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Abstract 
Platinum-based drugs are the established class of cancer therapeutics. Antiproliferative 
properties of the compounds were discovered in the 1960-s. Cisplatin, 
diamminedichloridoplatinum(II), was the first complex to show potency against cancer. 
Successful application encouraged chemists to search for better molecules in order to reduce 
severe side effects of cisplatin therapy and to broaden the application spectrum. The extensive 
search gave only several structures of cisplatin analogs, although thousands of complexes 
were synthesized. 
Oxaliplatin was the last one to be approved by the FDA (2002) and used worldwide for 
colorectal cancer treatment. It has lower oto- and nephrotoxicity compared to cisplatin. The 
easiest and most straightforward way to develop a new drug is to modify already existing 
ones, to optimize their structures. In some extent all the platinum-based drugs are cisplatin’s 
posterity. 
In this work, different modifications of oxaliplatin are described. In the first project the 
methyl-substituted cyclohexanediamine ligands were synthesized and corresponding 
oxaliplatin derivatives were obtained. This small substituent may take different positions 
related to the cyclohexane ring: both axial and equatorial isomers were prepared, 
characterized with NMR, elemental analysis and mass spectrometry. Their biological activity 
was tested in vitro and in vivo. In cytotoxicity tests, the one with axial orientation of the 
methyl group showed better results, the IC50 values were generally lower compared to 
oxaliplatin. The isomer with an equatorial orientation of the methyl group showed comparable 
or slightly higher values. The results of in vivo investigations were the opposite, in tests on 
leukemia mouse models better activity was shown by the equatorially substituted oxaliplatin. 
It’s also noteworthy to mention, that general toxicity was lower compared to oxaliplatin, what 
allowed increasing dosage of the drug. 
In the second project, conjugates of oxaliplatin featuring the TAT peptide (Trans-Acting 
Activator of Transcription) were prepared making the cellular transport more efficient. 
Inefficient delivery of complexes into the cell is one of the shortcomings of platinum-based 
therapy, and using delivery vectors could increase cellular accumulation of the drug. 
Oxaliplatin was oxidized to its Pt(IV) analog and equipped with a linker, capable of 
conjugation with a peptide via standard amide coupling. The peptide was synthesized on solid 
phase, the Pt complex was appended after the last amino acid. The obtained mono- and 
bisconjugates were characterized by NMR, ESI and MALDI MS and liquid chromatography. 
Both substances showed better cytotoxicity than the Pt precursor or the analogous amide 
without biologically relevant group.  
Zusammenfassung 
 
Platinbasierte Arzneistoffe sind etablierte Krebstherapeutika; die antiproliferative 
Eigenschaft der Komplexe wurde 1965 erstmals beschrieben. Diammindichloridoplatin(II) 
(Cisplatin) war der erste Komplex, der eine Wirksamkeit gegen Krebs zeigte. Die erfolgreiche 
Anwendung führte zur Entwicklung analoger Verbindungen, zur Minderung der schweren 
Nebenwirkungen und zur Erweiterung des Anwendungsspektums. Trotz der Synthese 
tausender Cisplatin Analoga, konnte nur wenige mit einem interessanten Wirkspektrum 
identifiziert werden. 
Oxaliplatin wurde als letzter Platinkomplex 2002 von der FDA zugelassen; es ist derzeit 
nahezu weltweit zur Behandlung von kolorektalen Karzinomen im Einsatz. Im Vergleich zu 
Cisplatin hat es eine niedrigere Oto- und Nephrotoxizität. Die einfachste Art, neue Wirkstoffe 
zu entwickeln, ist bereits bekannte Wirkstoffe zu verändern, immer im Hinblick auf eine 
Optimierung der Struktur-Aktivitäts Beziehungen. Gewissermaßen sind alle platinbasierten 
Therapeutika ein direktes Derivat des Cisplatins. 
In der vorliegenden Arbeit wurden unterschiedliche Derivate des Oxaliplatins entwickelt. 
Im ersten Projekt wurden methylsubstituierte Cyclohexandiaminliganden synthetisiert, und 
die entsprechenden Oxaliplatinanaloga hergestellt. Der kleine Substituent (Methylgruppe) 
kann unterschiedliche Positionen im Bezug auf den Cyclohexandiaminring einnehmen, 
sowohl das axiale, als auch das equatoriale Isomere wurden hergestellt und mittels NMR, 
Elementaranalyse und Massenspektrometrie eindeutig charakterisiert. Die biologische 
Wirksamkeit wurde in vitro und in vivo getestet. Das Isomer mit der axial orientierten 
Methylgruppe zeigte bessere Ergebnisse bezüglich der IC50 Werte, diese waren im 
Allgemeinen niedriger im Vergleich zu Oxaliplatin. Das Isomere mit der equatorial 
orientierten Methylgruppe zeigte vergleichbare oder etwas höhere IC50 Werte. Der Effekt in 
der in vivo Untersuchung (Mausmodell, L1210) war jedoch entgegengesetzt, das equatorial 
substituierte Oxaliplatin zeigte eine bessere Aktivität. Bemerkenswert ist in diesem 
Zusammenhang auch, dass die systemische Toxizität niedriger war im Vergleich zu 
Oxaliplatin, was die Erhöhung der Dosierung ermöglichte. 
Im zweiten Projekt wurden zur Effizienzsteigerung des zellulären Transportes, neuartige 
Konjugate bestehend aus Oxaliplatin und dem TAT Peptid (Trans-Acting Activator of 
Transcription) synthetisiert. Die ungenügende Akkumulation der Komplexe in der Zelle ist 
einer der wichtigsten Probleme der platinbasierten Therapie; eine Steigerung der zellulären 
Anreicherung kann mittels Verwendung geeigneter Trägermoleküle gemäß des Konzeptes des 
Drug targeting erreicht werden. Hierbei wurde Oxaliplatin zu dem entsprechenden Pt(IV) 
Analogon oxidiert und mit einem Linker, der mit einem Peptid mittels Amindkopplung 
verknüpft werden konnte, ausgestattet. Das Peptid wurde durch Festphasensynthese 
hergestellt, wobei der Platinkomplex nach der letzten Aminosäure angefügt wurde. Die 
isolierten Mono- und Biskonjugate wurden mit NMR, ESI und MALDI MS bzw. 
Flüssigkeitschromatografie charakterisiert. Die beiden Substanzen zeigten eine bessere 
Zytotoxizität im Vergleich zum Ausgangskomplex bzw. zu einem Amidanalogon, das keine 
Gruppe im Sinne des Drug Targetings aufwies. 
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 I. Introduction 
1. Drug Design 
1.1 Rational Drug Design in a Historical Prospect 
Therapy as a phenomenon cannot have any clear beginning in human history. The wish to 
be cured and get rid of pain is as basic as hunger. Without any doubt, people got sick, and 
consequently they tried to find cures, exactly as we do now. One can speculate that instincts 
were much more important at the early age of mankind, and treating wounds, finding medical 
plants can be described as their extrapolation. The development of healing into modern drug 
design was by no means straightforward, the way often led into a dead end, it was a child of 
its time. 
The beginning of European medicine is often counted from Hippocrates, he used a 
scientific approach based on observation. Previously, it was a mixture of superstition, magic 
and religion,1 the general explanation was provided exceptionally by belief. In ancient Egypt 
benign and malicious tumours were already known, and natural substances like castor oil and 
pig’s ears were used for treatment.2 Hippocratic medicine had a different base – diseases had 
natural causes, medicine was thus transferred from irrational field into a (more) rational 
philosophy. The title of his book “On the Sacred Disease” about epilepsy already contains the 
starting point for his polemic: he described it not as a divine, but as a hereditary disease of the 
brain where the soul and feelings were located. According to his concept of 4 humours:3 
"The body of man has in itself blood, phlegm, yellow bile, and black bile; these 
make up the nature of the body, and through these he feels pain or enjoys health.  
Now, he enjoys the most perfect health when these elements are duly proportioned 
to one another in respect to compounding, power and bulk, and when they are 
perfectly mingled.  Pain is felt when one of these elements is in defect or excess, or 
is isolated in the body without being compounded with all the others." 
Imbalance of liquids would cause disease, which could be treated by balancing the 
humours of a patient. 
A similar scheme existed in Chinese medicine. Organs were classified according to five 
basic elements of nature. Together with successful application of vegetable remedies, other 
substances bearing a symbolic and metaphorical meaning were used like rhinoceros horn or 
tiger penis. Ascription of healing potency, based on some other properties of the object, – 
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 could it be called in modern language a “rational drug design”? Compensating excess of yin 
with yang-food – isn’t it rational decision? The only difference is the rationale itself. 
One can consider rationality to be an accumulation of empirical facts and their 
metamorphosis into a new concept of cause-effect relationship. Depending on depth of the 
insight into the matter the concept of “therapy” changed. If Hippocrates is called a father of 
medicine, Paracelsus is the father of pharmacy. Like his predecessors, he considered bodies to 
consist of several basic elements. He distinguished between three of these: Salt, Mercury, and 
Sulphur. These are the names of elements we still use nowadays, but the meaning changed 
considerably:4 
A different Sulfur is found in gold, another in silver, another in iron, lead, zinc, 
and so forth-the same is true of Salt and Mercury. They are still more divided, so 
that there is not only one kind of gold, hut many kinds of gold, just as there is not 
only one kind of pear or apple but many kinds. Therefore, there are just as many 
different kinds of Sulfurs of gold, Salts of gold, Mercuries of gold. 
Paracelsus used both organic and mineral compounds to treat different diseases, some of 
them may seem to be absurd, but still there is rationality behind it. In the end of the 15th 
century, a violent epidemic of syphilis occurred in Europe. It was either imported from the 
New World or existed previously, but had mutated considerably. Paracelsus had his own 
explanation: it was caused by astral constellation of Venus combined with sexual libertinism.5 
His treatment was in accordance with the proverb “Two minutes with Venus, two years with 
Mercury”: the patients were prescribed mercury to balance the elements in the body and to 
excrete the disease with saliva, three pints needed to be produced in order for the treatment to 
be considered effective. 
Mercury was used conventionally for syphilis treatment till the beginning of the 20th 
century. By that time, the first exact analyses and syntheses of pure substances became 
possible. With the boom of organic chemistry, the new methods of experimental tests laid the 
foundation for pharmacy, and by the end of the century it became science.6 
1.2 Base of Modern Drug Development 
In 1878 the medicine student Paul Ehrlich wrote his dissertation titled “Contributions to 
the Theory and Practice of Histological Staining”. Injecting dyes into living organisms, he 
observed that cells of different organs were stained in different ways. The blood cells and 
microorganisms were of special interest to him. Ehrlich wanted to stain them without 
affecting other tissues. The successful experiments encouraged him to set a new task: to make 
4
 these selective substances toxic for microorganisms. He spent years treating samples with 
chemically modified substances to achieve this goal. The idea was revolutionary at that time, 
and nowadays it’s the common method of drug development.7 
“In a first place we want to affect the parasites solely, that means we need to learn to 
target, to target chemically. For this purpose the methods offer possibly versatile variation of 
considered substances on a way of chemical syntheses.” 
In 1863 the French pharmacist Antoine Béchamp synthesised an arsenorganic compound, 
which was named “Atoxyl” (Figure 1) because of the low toxicity observed. The observation 
turned out to be wrong, after using the substance in Africa for sleeping dropsy treatment a 
serious side effect was found – the drug was affecting the optic nerve. 
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Figure 1. Atoxyl, arsonophenylglycin and salvarsan (depicted in monomer forms) 
 
Following his concept, Ehrlich started to vary the structure, and after some hundreds of 
trials a first success was achieved. It was “arsenophenylglycin”, compound number 418. The 
substance was not really effective for the treatment of sleeping dropsy, but showed potency 
against spirochetes and, at the same time, low toxicity. Research was carried out further, tests 
were performed on the first feasible animal model, syphilis infected rabbits brought from 
Japan. The investigation of analogous compounds revealed the most interesting one, number 
606. Toxicity was lower as compared to the derivatives of As(V) due to the intentionally 
changed oxidation state of arsenic in the molecule following the idea of bioreduction of 
arsenic in the human body. One year later, the substance was marketed under the name 
salvarsan. 
The proposed structure with As=As (by analogy with azo compounds) was under debate 
almost until present. In 2005 ESI-MS investigation showed that the predominant species in 
5
 aqueous solution are rings with 3 and 5 As atoms in the molecule.8 
The discovery and strategy of structure optimization of salvarsan were important but 
maybe of even higher importance were the concepts proposed by Ehrlich. The investigations 
on “toxin – antitoxin” interactions of the natural toxins abrin and ricin, the experiments on 
“natural and acquired immunity” led to in his general “side-chain” theory. By the “side 
chains” he meant macromolecules on surface of a cell that could interact stoichiometrically 
with their counterparts (e.g. toxins – antitoxins) on the cell surface. In 1900, he introduced the 
term “receptor” instead of “side-chain”. The principle that toxins, nutrients and drugs bind 
selectively and the observation that tissues could be stained with different dyes, allowed him 
to establish connection between a chemical structure of the applied compounds and the nature 
of a biological object. Extrapolating these molecular interactions he proposed the idea of a 
“magic bullet” – an absolutely selective drug. His statement “wir müssen chemisch zielen 
lernen” (“we have to learn how to aim chemically”) as well as the strategy of optimizing 
chemical structure became the new paradigm for chemical treatment of the 20th century 
(Figure 2). Much later, his idea was realized literally in antibody therapy of, for example, non-
Hodkin lymphoma,9 and was conceptually implemented in targeted therapy. But the general 
principle was applied much sooner. During tests on nitrogen mustard as a potential chemical 
weapon, an unexpected property was discovered: it was more toxic to lymphoma and 
myeloma cells as compared to healthy ones and in 1942 clinical trials for lymphoma treatment 
were started. The ongoing development of molecular biology allowed deeper insights into 
molecular mechanisms of the mustard gas’s action: DNA was found to be the target. A search 
for agents, that were potentially reactive towards DNA, started after establishing this fact. 
One of the first successes were the synthetic nucleobases, fluorinated pyrimidines, which 
were prepared to hinder the replication process in 1957.10 
Afterwards, a plenitude of DNA-attacking molecules was discovered. They were modified 
and brought to clinical practice, still making use of the same principle – to stop DNA 
polymerisation and thus cell division.  
6
  
Figure 2. Progress in drug developments starting from Ehrlich’s “Side-Chain Theory” 
(taken from ref. 11) 11 
 
Further investigation of carcinogenesis revealed other cell targets, potentially useful for 
developing therapies: the cell proliferation could be interfered at any stage of the cell cycle. 
Cyclin-dependent kinases were found to be an attractive object of investigation due to their 
abundance and necessity in all cells. The close structural similarity of many kinases and thus 
possible interactions of a drug molecule with more then one of them changed the Ehrlich’s 
postulate of the “magic bullet” (one drug –  one target) into a “multitargeted drug”, a shotgun, 
to spread Ehrich’s metaphor.12 
The principle of drug design, laid by Ehrlich and successfully used in development of 
salvarsan, may be considered to be rational, but it was not the optimization, it was variation of 
structure to achieve better therapeutic impact. This kind of half-blind search was extensively 
used in the second half of the 20th century. Plenty of compounds, usually, organic ones, were 
screened for their biological activity, and this work resulted in an enormous amount of 
information on physical, chemical and biological properties. With the development of 
synthetic techniques, combinatorial synthesis became possible but the results were rather 
disappointing. The number of usable hits and consequently the value of the method, was very 
low, although the quantity of synthesised substances was enormous.13 
7
 1.3 Langmuir’s Approach 
The connections between composition and properties of substance were the core idea of 
chemistry since Mendeleev’s systematization of the elements. Hammet demonstrated the 
influence of structure on the reactivity of organic compounds in the 1930-ies. His theory 
became useful in predicting biochemical properties of the substances. Although empirical, it 
could quantify the influence of substituents on sterical and electronic properties, molar 
refractivity and lipophilicity.14 
Hammet’s outlook was a consecutive, but definitely more exact development of the 
concept proposed by Langmuir in 1919. His article “Isomorphism, Isosterism and 
Covalence”15 begins with the previously formulated ideas on structure of matter: “In recent 
papers I have described a theory of valence which I have called the octet theory.” Further the 
scale is enlarged, comparing physical properties of numerous gases and inorganic salts (both 
cations and anions), he called the compounds with similar properties isosteres. In some cases 
their resemblance is rather concealed: N2 and CO, F ¯ and O
2
¯, He and Li+, the conclusions on 
the base are even more surprising: “The relation between argon and nitrogen enables us to 
trace an equally close relationship between the cyanogen and the chlorine ions”, but the 
concept was largely applied in biochemical research. 
The term “bioisosterism” was introduced by Friedman in 1951, then was redefined as 
“compounds or groups that possess near-equal molecular shapes and volumes, approximately 
the same distribution of electrons, and which exhibit similar physical properties.”  
Similarity of atomic radii of hydrogen and fluorine allow this isosteric replacement, the 
strategy was successfully pursued in the development of 5-fluorouracil, a synthetic inhibitor 
of thymidylate synthase. The enzyme is necessary for DNA replication, and its strong 
covalent binding to 5-fluoro-2’-deoxyuridylic acid (metabolite of 5-fluorouracil) results in 
deactivation and thus ceases cancer cell proliferation. The small spatial difference between 
uracil and its fluorinated analogue allows successful mimicking, while a strong difference in 
electronegativity of H and F change their interaction with the enzyme significantly.16 
Not only atoms, but whole groups can be substituted according to their isosterical 
properties. The first attempt to classify them scientifically was performed by Grimm in 
1929.17 He arranged isosters (“pseudoatoms”) in columns: 
8
  
Figure 3. Isosteric replacements, proposed by Grimm 
 
This approach can be efficient in the case that the synthesis of multiple drug candidates 
was not troublesome and economically unrealistic, but it covers only known molecules, either 
discovered drugs or extracted from natural material. Later the strategy was called “Ligand-
Based Drug Design”, as opposed to the “Structure-Based” one. 
Improved preparative methods afforded straightforward synthesis of desired structures, 
but not all of them could be subjected to biological testing. In order to increase the efficiency 
of biological screening, filters were required to guide the chemist to the optimal result. The 
most famous of these filters is Lipinski’s rule of 5, based on the statistical analysis of 
properties of thousands of drugs. Similarities among them allowed to formulate the following 
rules for a drug to have bad absorption and permeation:18 
 
There are more than 5 H-bond donors (the sum of OH's and NH's)  
The molecular weight is over 500 
The Log P is over 5 (or MLogP is over 4.15)  
There are more than 10 H-bond acceptors (expressed as the sum of Ns and Os);  
Compound classes that are substrates for biological transporters are exceptions to the rule. 
 
The sum of criteria gave a new tongue-twisting adjective to describe a compound as a 
potential medicine – “drugelikeness”. The established paradigm was abundantly quoted and 
motivated many researchers to expand it, to find further characteristics of molecules that 
could be useful for their biochemical application. In 2001, Oprea noticed that 70% of drug-
like compounds had between zero and two hydrogen bond donors, between two and nine 
hydrogen bond acceptors, between two and eight rotatable bonds and between one and four 
rings. Verber found other parameters to be important for oral bioavailability of drugs in rat: 
9
 the number of rotable bonds has to be smaller than 10 and a polar surface not larger than 
140Å.19 
As Ehrlich proposed and was established experimentally later, the drug molecule reaches 
its target in the body. The complimentary (to structural variation) approach is to investigate 
the target itself and to find out how to facilitate its interaction with a drug molecule. 
Potentially interesting proteins (targets) are isolated and cloned. Numerous NMR methods, X-
ray crystallography and mass-spectrometry give information on the 3D structure in the solid 
state and in solution. When the geometry is known the active site can be found. The pocket is 
packed either with a molecule from a database, or the filling is constructed from atoms and 
functional groups. Further operations are performed in silico, so called de novo drug design 
(Figure 4). After the shape of a drug is determined, other properties, necessary for effective 
binding, are computed. Complex binding of a small molecule and a target consists of 
hydrogen bonding and hydrophobic and electrostatic interactions. The first being the strongest 
among them, this determines the key interaction site of the pair and narrows down the range 
of possible structures.20 
 
 
 
Figure 4. De novo drug design (Taken from reference 20) 
 
 
 
10
 2. Platinum-Based Therapy 
2.1 Platinum Drug Development 
Cisplatin, the first platinum-based drug, was discovered accidentally but not by chance. In 
1961 young physist Barnett Rosenberg investigated the influence of an electric field on the 
growth of Escherichia Coli bacteria. The idea, or better to say, the intuition behind consisted 
in the similar appearance of a mitotic spindle and the lines of a magnetic field (Figure 5), seen 
on iron filings around a magnet bar. “It looks like a dipole field,” – he said.21 
   
Figure 5 Spindle apparatus (left) and iron spinings in magnetic field (right) 22 
 
Electrical current passed through a medium with E. Coli inhibited bacteria division. 
Thorough examinations of the experiment parameters (frequency of voltage, pH, presence of 
oxygen, temperature, UV irradiation) were carried out. The exploration reminded more of a 
detective story, than a cold scientific report. Finally, a substance was proposed to be 
responsible for the cease of bacteria division (and not the electric current itself). It was a 
platinum salt (NH4)2[PtCl6] which was formed upon attack of chloride ions from the 
electrolyzed solution on platinum electrodes.23 Other metal compounds were tested as well, 
and rhodium salts also caused bacteria elongation. The nature of the effect was unclear. The 
role of oxidation state of metal, ligands around them and the geometry of complexes were 
stressed as undefined. As was established in a pioneering work on biological effects of 
inorganic compounds in 1931, not the metal alone, but also its companions should be 
considered.24 The authors tested metals and their salts dissolved in physiological solution and 
suspended in olive oil if the solubility was too low. These were injected subcutaneously to 
trace the patterns of biological effects, and found metals in zero oxidation state to be 
ineffective. The most fundamentally important statement was that “similar compounds of the 
same metal often show absolutely different impact.” 
This was proved in further investigations of Rosenberg, when cis- and trans-isomers 
(Figure 6) of [PtCl4(NH3)2] were synthesized separately and tested on E. coli. The trans 
11
 complex was inefficient as an inhibitor of bacteria division, but the cis species showed the 
same activity as was observed in the experiment with platinum electrodes. Simultaneously, 
the corresponding Pt(II) complexes were tested. Again, the cis isomer was effective and trans 
did not show any impact.25 
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Figure 6. cis- (left) and trans- (right) diamminedichloridoplatinum (above) and their 
corresponding Pt(IV) analogs (below) 
 
This was the first structure-activity relation that afterwards had been proved for the 
analogues of initial cisplatin. Two possible explanations for the configuration were proposed: 
1) trans-complexes are hydrolysed significantly faster and thus react faster and less 
selectively, 2) cis-complexes can form chelates which could be the reason for antitumor 
activity. Numerous analogues of the parental structure (focusing on the cis-configuration) 
were synthesized and tested for biological activity. 
Very soon after Rosenberg’s discovery, in 1970, DNA was suggested to be a target for the 
complexes.26 Some similarities to alkylating agents like mustard gas were found. The 
anticancer activity could be explained by intrastrand DNA cross-linking based on the 
possibility of cis-isomers to form chelates. Because of this parallel, cisplatin was classified as 
“alkylating” type of anticancer drugs (or “alkylating-like” sometimes), although the pure 
inorganic molecule has nothing to do with organic alkylation reactions. After intravenous 
injection, cisplatin diffuses into the cells (passively or supported by copper transporters) and 
undergoes aquation. In the bloodstream the reaction is supressed by a higher chloride 
concentration, but the intracellular concentration is much lower and the dichlorido complex is 
activated for DNA-attack. The most favourable coordination site of DNA is the electron-rich 
N7 atom of guanines (Figure 7) and adenines. After formation of the monoadduct, another 
chloride is substituted by neighbouring nucleobase. Intrastrand (i.e. located on the same strand 
of DNA) cross-links with two neighbouring guanines are the most common adduct for 
cisplatin. As a result, the DNA replication is hindered, which leads to apoptosis.  
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Figure 7. Hydrolysis of cisplatin, formation of N7-guanine monoadduct, and its 
conversion into intrastrand G-G crosslink 
 
The successful treatment and rapid approval by the American Food and Drug 
Administration in 1978 (first trials began in 1971) was a strong impulse for the search for 
complexes with improved properties as some tumours turned out to be resistant to cisplatin 
and additionally severe side effects of the therapy were observed. Thousands of complexes 
were synthesized and tested for anticancer activity, and soon further regularities were 
established: chlorido ligands react, and ammoniac molecules remain coordinated. Structure 
variations and studies on their biological impact were performed already in 1973 within less 
than 10 years after discovery of the Pt-induced cellular effects.27 Higher lability of 
dissociating ligands such as H2O, NO3
- resulted in immediate and unselective toxicity, and 
inert leaving groups like rhodanido and nitrito decreased the potency of complexes as they 
hinder hydrolytic activation and the following intracellular reactions. The range of labile 
ligands is limited to halogens and O-donors, because some softer atoms like P, S form too 
strong bonds with the soft Pt central atom. The (pseudo)halogenido ligands were exchanged 
against chelating oxalate and malonate and these complexes showed promising results in 
some cancers. The strategy of increasing drug stability using chelates brought a second 
generation drug with lower nephro- and neurotoxicity – carboplatin (Figure 8). The adducts 
formed with DNA are the same due to the same ammine ligands. A reason for decreased side 
toxicity is the hydrolysis rate. 
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Figure 8. Approved Pt-based drugs with dicarboxylates as leaving groups, carboplatin 
(left) and oxaliplatin (right) 
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 2.2 Rules of Activity 
 
 
Figure 9. Development of Pt-based drugs (taken from reference 28) 28 
 
The leaving group determines the reactivity of complexes, the am(m)ine fragment is 
responsible for steric properties and lipophilicity. The highest activity was observed for 
ammonia and primary amines. Any further substitution at the nitrogen atom decreased activity 
and solubility of the complexes, exceptions are rare. Also, interactions of hydrogens at the 
coordinated nitrogen atom with biomolecules were expected to play an important role in the 
activity of the drug. 
The empirical facts were summarized in four rules, necessary for anticancer active Pt(II) 
complexes:28 
1) The complex should be uncharged. 
2) cis-Configuration of the leaving groups is essential. 
3) Lability of leaving groups should be comparable with to the one of chlorides in 
cisplatin. 
4) The other ligands should be inert and neutral.  
The 4 rules left not much space for structure variation. They were expanded to another 
oxidation state of Pt. Investigation of Pt(IV) complexes revealed the necessity of cis- 
configuration of amine ligands as well (1975),29 and it was demonstrated in 1985, that  
antitumor activity of Pt(IV) complexes is in fact the activity of Pt(II) analogues, that are 
generated upon reduction of the initial species.30 
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 All Pt-based drugs, approved for marketing or being candidates for approval follow the 
rules, which can clearly be seen on a superposition of structures of these complexes. 
 
Figure 10. Superposition of approved and promising Pt-based drugs. 
 
The rules facilitated the development of numerous active compounds, but together with 
guiding the researchers they narrowed their sight field and “the rule has sometimes been 
invoked more prescriptively”.31 
2.3 Rulebrakers 
As any framework, when pressure of contradicting facts is getting too high, it turns 
useless. These four rules lost their validity upon subsequent investigation of Pt complexes and 
as insight into biological action became deeper. The majority of complexes that possess the 
described properties were significantly less active as compared to cisplatin. cis-Complexes 
with linear alkylamines lost their activity with the elongation of the hydrocarbon chain, 
branched alkyl radicals did not show good results as well. 
The first trans complexes to demonstrate higher cytotoxicity as compared to the 
corresponding cis isomers were discovered in 1989.32  
A fast hydrolysis rate was found to be one of the reasons for decreased activity of trans 
isomers. The active hydrolyzed species were undergoing faster side reactions and were unable 
to reach the DNA. But the 5-fold difference in ID50 values of trans and cis dipyridine 
complexes could not simply be explained with the hydrolysis rate as they were found not to 
differ dramatically and the obtained facts entailed more questions than answers. 
If rapid hydrolysis is undesired, it should be hindered. Knowing that the ligand-exchange 
reaction proceeds via a 5-coordinated intermediate state, it could have been slowed down by 
bulkier substituents hindering the axial positions of the complex. The concept was used for 
the preparation of trans-complexes with quinoline ligands.33 Significant activity of the 
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 compounds with trans-configuration was also observed in Pt(IV) analogues as well as 
complexes with a bulky cyclohexylamine substituent. 
Approximately at the same time, in 1989, the rule of neutrality was violated.34 Activity of 
cisplatin analogues with one chloride substituted for heterocyclic amines in murine tumour 
models was higher than that of cisplatin itself. In 1991 both rules of cis-configuration and 
zero charge were broken by Gibson et al, when the covalent binding of Pt complexes to DNA 
was reinforced with the intercalating properties of an appended antraquinone ligand. The 
isomers (cis and trans, Figure 11) showed similar activity.35 
O
O (CH2)n
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H3N NH3
O
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NH2
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Cl NH3  
Figure 11. cis- (left) and trans- (right) isomers of Pt(II) complexes 
with an antraquinone ligand 
 
Multinuclear platinum-based complexes first described by Farrell,36 can also be 
considered as trans-configured ones. The trans position to chlorine is occupied by a diamine 
linker, that transfers the second DNA binding site to another metal centre. 
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Figure 12. Di- and trinuclear Pt(II) complexes with linear linkers 
 
The idea behind designing these compounds was to make different DNA adducts possible, 
that would be recognized and repaired in a different way in order to overcome cisplatin 
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 resistance. Numerous linkers of different nature were introduced between two platinum 
moieties.37 Complexes with bridging azoles showed activity in a cisplatin resistant cell line, 
and investigation of their binding showed isomerization of nucleobase adducts, which could 
lead to different DNA distortions and thus recognition.38  
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Picture 13. Dinuclear Pt(II) complexes with bridging azoles 
 
The platinum fragments were linked via linear polyamines with prospect of hydrogen 
bonding between the central amino group and H-donors of the DNA, but the best results were 
obtained by a trinuclear complex with one additional platinum moiety as linker. This is the 
only non-classical compound (i.e. rule-braking) to pass Phase II clinical studies.39 A 
noteworthy fact is, that the total charge of the trinuclear complex cation is 4+. 
2.4 Pt(IV) Complexes as Anti-Cancer Drugs 
The only thing that remained of the initial rules is the classification: complexes that obey 
the rules are called “classic” ones, all others “non-classic” complexes. But there is a vast class 
of platinum complexes that were already considered by Rosenberg, but left aside in further 
development, namely Pt(IV) complexes. 
The first promising Pt(IV) compound was cis,trans,cis-dichloridodihydroxido-
bis(isopropylamine)platinum(IV), initially named CHIP and then “iproplatin” (Figure 14). 
Comparison with cisplatin (called in that paper “neoplatin”) showed an equal antitumor effect 
and lower toxicity.40 The importance of the development of analogues with smaller side 
effects like hearing loss and nephrotoxicity brought the compound into phase I clinical 
trials.41 In further examinations, the cross-resistance with cisplatin was stressed as an 
advantage of the compound,42 but the activity in phase II was just modest.43 
The second Pt(IV) compound brought into investigation was tetrachlorido(dl-trans)-1,2-
cyclohexanediamineplatinum(IV) called tetraplatin (Figure 14). The stated rationale was 
again the cisplatin resistance and the limited range of responsive cancers.44 Nevertheless, its 
toxicity (neuropathy) was higher than the therapeutic effect and it was abandoned. 
The structure of tetraplatin was synthetically completed, and no further modifications 
17
 were possible, besides a non-leaving cyclohexanediamine moiety. Iproplatin with its two axial 
hydroxido groups had more space for modifications. In 1992, Khokhar used common reaction 
of organic chemistry to modify dihydroxido Pt(IV) complexes – they reacted as alcohols, 
forming inorganic ester analogues. A series of different carboxylato complexes was 
synthesized, and trifluoracetato derivatives were found to be more effective when compared 
to acetato ones. This could be explained by a higher lipophilicity of the trifluormethyl groups, 
but an influence of the stronger inductive acceptor on the reduction of the Pt(IV) complex to 
its Pt(II) analogue was also not excluded.45 Recently, it was established that not the potential 
alone is responsible for reduction, the thermodynamically driven reaction also faces a kinetic 
obstacle. Electron transfer is facilitated by the formation of a bridge between complex and 
reducing agent, thus the reaction rate is very slow, when the coordination sphere consists only 
of amines and carboxylates.46 
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Figure 14. Pt(IV) candidates: iproplatin, tetraplatin and satraplatin 
 
In 1993 another Pt(IV) compound was prepared as a potentially orally available drug by 
Kelland et al. and Brystol-Myers: JM216, later on named satraplatin. Four years before an 
attempt to introduce carboplatin orally caused nausea and vomiting even when offered in 
lemonade syrup and adsorption was poor compared to intravenous injection.47 A Pt(IV) 
formulation was proposed due to higher kinetic stability of these complexes, two additional 
ligands increased lipophilicity, however the different mode of administration may have 
changed the pharmacokinetics of the drug.  
The easiest and most logical modification of satraplatin would be a variation of axial 
acetates. The ligands are cleaved upon reduction to the Pt(II) species, they do not affect 
binding to intracellular targets, but change the lipophilicity and the reduction potential of the 
complex. 
Acylated complexes could be afforded either via anhydrides or acid chlorides. The 
reaction of hydroxide complexes with cyclic anhydrides yielded molecules with a free 
carboxylic group,48 and the functionality was extensively used for derivatization. Activation 
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 and coupling reactions of carboxylic acids are well developed in organic chemistry and 
numerous esters and amides can be produced for the fine-tuning of lipophilicity of drugs.49 As 
delivery vectors also more complex molecules were appended like hormones,50 carbon 
nanotubes51 and peptides. 
The empirically determined and calculated properties of “rationally designed” Pt(IV) 
complexes were subjected to QSAR systematization with the declared goal to develop a 
reliable predictive model for cytotoxicity of complexes in given cell lines.52 Models could be 
built using experimentally determined parameters like lipophilicity and reduction potential or 
even calculated numbers of C, N, O atoms in a molecule: 
log1/IC50(ovarian)= −0.015 + 0.25(±0.03)nCs – 0.27(±0.07)nO, 
where nCs is the number of sp3 carbon atoms, and nO the number of oxygen atoms. 
One can also see from the equation that the more carbons the molecule contains, the 
higher is its cytotoxicity. Lower water solubility of compounds with long alkyl residues is 
thus not considered. The importance of reduction kinetics and not only the potentials was 
mentioned above,46 and the contribution of reduction potential in vivo may significantly differ 
from cytotoxicity tests. 
As one can see, this regression model is applicable only to closely related compounds and 
may be considered a compact form to describe the IC50 values of a class of substances for a 
given cell line, but is not the optimal tool for finding new drugs. 
 
2.5 Other Strategies for Improvement 
 
Besides the variation of a drug structure itself, combinations of already established drugs 
with supportive pharmaceuticals were extensively investigated. One of the reasons for a lower 
activity of Pt compounds in many cancers is the binding of complexes to glutathione 
(cysteine-containing tripeptide), and buthionine sulfoxime was used to suppress glutathione 
synthesis.53 Another reason for cisplatin resistance is mismatch repair, and addition of DNA 
demethylating agents helped to sensitize tumours resistant to cisplatin.54 The addition of 
bevacizumab, an antibody targeting the vascular endothelial growth factor receptors, to the 
carboplatin – paclitaxel regimen improved overall survival by “increase of drug delivery” to 
the tumors.55 In reality, the medicine was not target-oriented (i.e. brought to the tumour), but 
could reach it more easily. 
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Figure 15. Aroplatin and prolindac, carrier-supported drugs 
Drug delivery in its literal sense is yet another booming area in pharmacy, and platinum-
based drugs are not an exception. One strategy exploited was to trap cisplatin into PEG-ylated 
micelles in order to increase its stability in blood. The formulation got the name “Lipoplatin”, 
it was clinically investigated parallel to free cisplatin and carboplatin. The Phase III trials 
showed lower toxicity together with retained activity in non-small cell lung cancer.56 Slow 
release of cisplatin from liposomes is the main problem of the application of the drug, and 
ultrasound was applied to increase its availability. The method, though, is limited to 
superficial tumours, because ultrasound cannot reach deeper tissues.57 The type of cancer 
seems to play an important role in Lipoplatin: early attempts to treat osteosarcoma in dogs 
were not successful, probably because of the low availability of cisplatin. The osteosarcoma is 
less relevant as a cancer model, because it misses leaky vasculature important for drug 
accumulation in the tumour region.58 
Another goal was set to encapsulate cyclohexanediamine complexes of platinum with two 
lipophilic carboxylates. Liposomic formulations made administration of water-insoluble 
compounds possible and the efficiency of encapsulation was also increased as compared to 
cisplatin.59 Development of this strategy resulted in aroplatin (Figure 15), an encapsulated 
(R,R-1,2-cyclohexanediamine)-bis(neodecanoato)platinum (II), that was tested in phase II as a 
drug candidate for colorectal carcinoma. It was well-tolerated and similarly active to 
oxaliplatin.60 
A similar logic stands behind the polymer-bound (R,R-1,2-cyclohexanediamine)platinum, 
prolindac (Figure 15), evaluated in phase II clinical studies.61 The long hydroxy-
propylmethacrylamide polymer chains should be retained in the leaky blood vasculature of 
tumours (enhanced permeability and retention effect, EPR) and upon hydrolysis of the 
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 amidomalonato group the DACH-platinum cation is released. The hydrolysis of complexes is 
faster at a lower pH, thus the selectivity for cancer sites is increased.62 
Liposomes, polymers, micelles and nanoparticles are used as carriers for drugs with 
selectivity based on macrocharacteristics of cancer like a lower pH in tumour area or leaky 
blood vessels. Later, platinum complexes were conjugated to short peptides with the RGD-
motive that are recognized by integrins upregulated on certain cancer cells. The peptide-
conjugated complexes showed higher efficacy compared to the single aminoacid derived ones 
and showed potential as more selective drugs.63 Besides the presented results, another aspect 
is important in the article. The tethered peptides are called “tumour-targeting-device”. 
Appending receptor-binding peptides is also integrated into the term “targeting”, but the term 
is not quite clear even on the webpage of he National Cancer Institute (NCI). “Targeted 
therapy” is defined as “a type of treatment that uses drugs or other substances, such as 
monoclonal antibodies, to identify and attack specific cancer cells,” 64 but even in the 
factsheet of the same institute a more detailed description says: “Targeted cancer therapies are 
drugs or other substances that block the growth and spread of cancer by interfering with 
specific molecules involved in tumor growth and progression. Because scientists often call 
these molecules “molecular targets,” targeted cancer therapies are sometimes called 
“molecularly targeted drugs,” “molecularly targeted therapies,” or other similar names.” 65 
“Targeting” and all its paronyms thus became a symbol of new, better – rational drugs. 
Market analyses already describe them separate from classical anticancer therapeutics, 
because the growth of the integer oncology market is mostly attributed to rapid development 
of molecularly targeted drugs.66 The ratio of US sales of chemotherapies versus targeted 
cancer therapies changed from 0.84 to 1.28 within 4 years (Figure 16), which makes the 
concept of targeted therapy desirable in drug marketing. 
 
Figure 16. Market growth of targeted and classical chemotherapeuticals 
(fig. taken from the ref. 66) 
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 The adjective “rational” experienced the same fate, as “targeted”. On the same NCI 
webpage they are mentioned together: “targeted therapies are often referred to as the product 
of “rational drug design.” Osella et al. stressed, that the series of synthesized complexes was 
well thought-out, but in general the term is used for molecules adapted to their targets.67 
It is interesting to mention, that in the first article about Pt conjugation the peptide was not 
appended as a delivering moiety (Picture 17), guanidine residues (R1=(CH2)3NHC(NH)NH2, 
R2=H) of arginine should have changed the binding properties of the complex to DNA.68 
Soon, the synthesis was performed in an automated mode69 and a dinuclear complex was 
prepared,70 but none of the compounds showed any significant cytotoxic activity. In the 
investigated series of N-substituted ethylene diamine ligands with dipeptide fragment the best 
results were observed with least sterically hindering glycine derivatives (R1=R2=H), the 
lowest effect was observed with R2=Benzyl and R1=H, sending back to the old postulate of 
minimal substitution of the coordinated nitrogen atom.  
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Picture 17. Pt(II) peptide conjugate 
 
Peptide tethering of the leaving malonato group did not bring much success as well. In a 
thorough article of Gibson et al., the diammineplatinum fragment was appended to a nuclear 
localization signal (NLS), a short cationic peptide facilitating transport into the cell nucleus. 
The following molecules were synthesized and investigated:71  
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Picture 18. Conjugates of the diammine Pt(II) fragment with NLS (FITC = fluorescein 
isothiocyanate, PEG = polyethylene glycol) 
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 NLS was necessary for delivery, fluorescein allowed microscopic monitoring of label 
distribution within cells and PEG-ylation was performed analogically to other investigated 
non-platinum anticancer drugs. Confocal microscopy showed accumulation of NLS-vectored 
folic acid (a model cargo) in the nucleus. The molecules without peptide remained distributed 
in the cytoplasm. But the results of expriments with Pt-conjugates were unexpected: the 
unconjugated complex showed better cytotoxicity and DNA platination. The phenomenon 
was explained by insufficient activation of the initial molecule: before reacting with DNA, the 
complex needs to be hydrolyzed to form the active species cis-[Pt(NH3)2]2+ . Probably it was 
not efficiently released in the nucleus and the hydrolysis in cytosol was necessary. 
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Picture 19. NGR-tethered Pt(II) conjugates, R=H or R=C2H5. 
 
Conjugation to a different peptide indirectly proved Gibson’s assumption: when malonate 
was appended to a peptide with the NGR motif,72 able to bind to endothelium of angiogenetic 
blood vessels and tumour cells in murine breast carcinoma models, the uptake was 
significantly increased in parallel with cytotoxicity. In this case, the leaving group could 
dissociate in the cytoplasm, before the activated diam(m)ineplatinum cation reached DNA.  
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 3. Concluding remarks 
The complexes of Gibson should have also been a poor drug candidate according to the 
rules of Lipinski and Cleare: a high charge of the molecule due to 5 basic amino acids (and 
large polar surface area), probably, low lipophilicity because of the same reason and high 
molecular weight. But they were not potent because of absolutely different properties of the 
substance. Oxaliplatin conjugates with the TAT peptide, described in the second article 
enclosed, would also be bad candidates according to the listed requirements, but the cytotoxic 
activity was significantly better, compared to the unconjugated analogues.  
Insufficient cell uptake of cisplatin and its analogues remains one of the main problems of 
therapy, and increased influx of the drug can make them much more efficient. Pt(IV) 
complexes with axial ligands, which are cleaved upon reduction to Pt(II) derivatives, offer the 
best opportunity for drug delivery, because the reduction products are the investigated Pt(II) 
analogues. Amine ligands are responsible for the form of DNA adducts, chemical 
modification of their periphery has its optimum – in case of the cyclohexanediamines, the best 
results were observed with 4-methyl substituted rings, larger substituents decreased the 
activity of complexes.73 The leaving groups determine the hydrolysis (and thus activation) 
rate. Inert complex are vain, too reactive ones suffer side reactions before they reach DNA. If 
both groups can be optimized to their limit, the only remaining site is the axial position. 
Conjugation with carriers, delivery vectors, or any other molecules via cleavable linker offers 
the best strategy to modify properties of drugs, optimized for intracellular action in future 
development of platinum-based drugs. 
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{(1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically
Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo
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Novel derivatives of the clinically established anticancer drug oxaliplatin were synthesized. Cytotoxicity
of the compounds was studied in six human cancer cell lines by means of the MTT assay. Additionally,
most promising complexes were also investigated in cisplatin- and oxaliplatin-resistant human cancer
cell models. The therapeutic efficacy in vivo was studied in the murine L1210 leukemia model. Most
remarkably, {(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II), comprising an equa-
torial methyl substituent at position 4 of the cyclohexane ring, was as potent as oxaliplatin in vitro but
distinctlymore effective in the L1210model in vivo at the optimal dose. The advantage observed in the in
vivo situation was mainly based on a more favorable therapeutic index. The maximum tolerated dose
of the novel analogue was higher than that of oxaliplatin and caused a greater increase in life span
(>200% versus 152%), with more animals experiencing long-term survival (5/6 versus 2/6). These data
support further (pre)clinical development of themethyl-substituted oxaliplatin analogue with improved
anticancer activity.
Introduction
The cytotoxic properties of cisplatin, cis-diamminedi-
chloridoplatinum(II),1 were found by serendipity in Barnett
Rosenberg’s laboratory in 1965.2,3 Cisplatin was finally ap-
proved by the Food and Drug Administration (FDAa) in
1978. Exchange of the two chloride leaving groups of cisplatin
with the more kinetically inert 1,1-cyclobutanedicarboxylato
ligand resulted in carboplatin, cis-diammine(1,1-cyclobuta-
nedicarboxylato)platinum(II), which received approval in
1989 as second-generation platinum-based agent. In 2004,
the FDA approved the third generation platinum drug,
oxaliplatin (Figure 1), {(1R,2R)-cyclohexanediamine}oxalato-
platinum(II),4,5 for the first line treatment of colorectal carci-
noma in combination with 5-fluorouracil and leucovorin
(5-FU/LV); neurotoxicity was found to be dose limiting.6
Clinical trials based on different tumors of the gastrointestinal
tract and breast and lung carcinomas are ongoing. Remark-
ably, oxaliplatin shows a different spectrum of cytotoxicity
compared to cis- and carboplatin as deduced from the 60
cell line panel of the NCI, being in accord with its activity
in the inherently cis- and carboplatin resistant colorectal
carcinoma.7
Compared to cisplatin, the volumeof distribution (serves as
a measure, how effectively a drug is cleared from the blood-
stream and going into tissue) of oxaliplatin is considerably
high.Moreover, the terminal elimination phase is longer than
that for cisplatin.8 The mechanism of cellular oxaliplatin
accumulation is still unclear. In contrast to cisplatin, accu-
mulation of oxaliplatin in cancer cells is less dependent on the
copper transporter CTR1.9 Like cisplatin, the ultimate target
of oxaliplatin is the genomicDNAand it forms the same types
of inter- and intrastrand DNA cross-links as cisplatin,10,11
however, the reactivity toward isolated and cellular DNA is
lower.12 Because the cytotoxic potency of oxaliplatin is gen-
erally well comparable or even higher than that of cisplatin in
some cell lines, oxaliplatin-induced DNA adducts have to be
more cytotoxic than those arising from cisplatin.13 Cisplatin-
DNA adducts are effectively recognized by the MMR com-
plex and by HMG1 but not those adducts deriving from
oxaliplatin.14,15 Postreplicative bypass is also different and
more efficient past oxaliplatin-GG adducts.16 On a molecu-
lar level, the adducts of oxaliplatin17 and cisplatin18 with the
same dodecamer duplex were investigated by crystal structure
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d-OHP, S,S-enantiomer of oxaliplatin; ESI, electrospray ionization;
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mobility group protein; ILS, increase in life span; LV, leucovorin;
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National Cancer Institute; Py, pyridine.
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diffraction, revealing a relatively similar geometry. From that
point of view, it is difficult to understand the differences in
their cytotoxic potential. However, it has to be taken into
account that the situation in solution may vary from that in
the solid state as could be demonstrated recently.19
The cyclohexanediamine carrier ligand in oxaliplatin com-
prises a trans-1R,2R configuration with both amino substi-
tuents in equatorial position; the cyclohexane ring is situated
nearly perfectly within the square planar coordination
plane.20 The same holds true for the trans-1S,2S enantiomer.
In the case of the cis-1R,2S counterpart, one amino substi-
tuent is in an equatorial and the other in an axial position,
leading to a nearly perpendicular arrangement of the cyclo-
hexane ring with respect to the coordination plane.21 The
antiproliferative properties of all three (cyclohexanediamine)-
oxalatoplatinum(II) complexes have been investigated with
the following structure-activity relationship (DACH =
diaminocyclohexane): trans-1R,2R-DACH enantiomer >
trans-1R,2R/1S,2S-DACH racemate > trans-1S,2S-DACH
enantiomer>cis-1R,2S-DACH diastereomer.22,23 The differ-
ence between trans- and cis-configured complexes is easily
explainable by the shape of the cis analogue (perpendicular
arrangement of the cyclohexane ring). Indeed, due to steric
hindrance, adduct formationwithDNAwas slow andalso the
conversion of the monoadduct to the bisadduct.24 However,
in the case of both trans-isomers (same shape), the DNA
seems to act as chiral discriminator as could be shown by
Lippard and colleagues.17 Formation of a hydrogen bond
between the pseudoequatorial NH hydrogen of the (1R,2R)-
cyclohexanediamineplatinum(II) fragment andO6of aneighbor-
ing guanine was found, which is not possible in the case of
trans-1S,2S-configuration.
Finally, what we really do know about the mode of action
ofoxaliplatin andwhatmay serveasbasis for thedevelopment
of novel oxaliplatin derivatives with improved cytotoxic and
anticancer properties are: (i) distribution in the body and
cellular accumulation of cisplatin and oxaliplatin are different
and (ii) recognition and processing of DNA adducts are not
the same. These features are, at least in part, the result of the
trans-(1R,2R)-cyclohexanediamine carrier ligand, providing
lipophilicity along with steric bulk to oxaliplatin. Conse-
quently, we have focused on further increasing the lipophili-
city/steric bulk of the cyclohexanediamine moiety. Here, we
report for the first time on the synthesis, characterization, in
vitro cytotoxicity, and in vivo anticancer activity of a novel
enantiomerically pure oxaliplatin derivative, {(1R,2R,4R)-4-
methyl-1,2-cyclohexanediamine}oxalatoplatinum(II), ex-
hibiting an equatorial methyl group at position 4 of the
cyclohexane ring. We also demonstrate that bigger substitu-
ents (ethyl or t-butyl) do not lead to an improvement of the
cytotoxic and anticancer properties.
Results and Discussion
The aim of the present work was to synthesize close
analogues of oxaliplatin, which are equipped with an
increased lipophilicity, additionally having an influence on
the structure of adducts formed with the final target DNA.
Consequently, the intention was to improve the biological
properties of oxaliplatin and not to develop completely
different types of complexes (“The most fruitful basis for the
discovery of a new drug is to start with an old drug” Sir James
Black, Nobel Prize in Physiology or Medicine in 1988).25
The oxalato leaving group was left unchanged because it
affects the solubility, the biodistribution, and the systemic
toxicity but of course not the structure of DNA adducts. The
{trans-(1R,2R)-cyclohexanediamine}platinum(II) fragment
binds to DNA in the major groove (Supporting Information,
Figure S1), generating there anunpolar region/steric bulk.From
that point of view, it seems to be reasonable to derivatize the
fragment at position 4 of the cyclohexane ring (preferably in
equatorial position), offering a maximal distance from the
coordination site. Substitution at positions close to the metal
center, or even at the coordinated nitrogen atoms, would
significantly influence the structural changes of DNA adducts
and were therefore not favored.
Synthesis and Characterization. Racemic (1R,2R,4R/
1S,2S,4S)-4-methyl-1,2-cyclohexane-diamine was synthe-
sized as reported recently.26 Shortly, 4-methylcyclohex-1-ene
was converted into the vicinal trans-diol (Scheme 1) by
treatment with hydrogen peroxide in the presence of formic
acid. In a next step, the corresponding mesylate was formed
via reaction with methanesulfonyl chloride/pyridine, which
was then transferred with sodium azide into 4-methyl-
trans-1,2-cyclohexanediazide. The diamine was subsequently
obtained by reduction with hydrogen at Pd on CaCO3
(Lindlar’s catalyst).
Enantiomer separation of racemic (1R,2R,4R/1S,2S,4S)-
4-methyl-1,2-cyclohexanediamine was performed via recrys-
tallization of the respective L- or D-tartrates in an ethanol-
water mixture (Supporting Information, Scheme S1).
Enantiomerical purity was proven by chiral HPLC. Prior
to HPLC analysis, the diamines were derivatized with ben-
zyloxycarbonyl chloride in order to obtain UV-active com-
pounds (6 þ 7, Supporting Information, Scheme S1 and
Figure S2).
Enantiomerically pure (1R,2R,4R)-4-methyl-1,2-cyclo-
hexanediaminium L-tartrate, 1a, was then reacted with
K2PtCl4 in the presence of NaOH, resulting in the yellow
dichloridoplatinum(II) complex 2a. The chlorido ligands
were released with AgNO3 and addition of potassium
oxalate to the formed diaquaplatinum(II) species finally
resulted in the white target complex 3a, {(1R,2R,4R)-4-
methyl-1,2-cyclohexanediamine}oxalatoplatinum(II). The
corresponding 1S,2S,4S-enantiomer 3b was obtained by
following the same procedure and starting from (1S,2S,4S)-
4-methyl-1,2-cyclohexanediaminium D-tartrate 1b.
Oxalatoplatinum(II) complexes 3a and 3bwere fully char-
acterized by elemental analysis and multinuclear (1H, 13C,
and 195Pt) one- and two-dimensional NMR spectroscopy.
The coordination sphere around the platinum atom can best
Figure 1. Structures of oxaliplatin and the novel enantiomerically pure oxaliplatin derivatives with either equatorial (3a) or axial (3c) methyl
substituent with NMR numbering scheme.
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be judged by measuring a 195Pt NMR spectrum. The reso-
nance at -365 ppm for 3a (Figure 2) is indicative for a
PtN2O2 coordination and is in accordance with the chemical
shift found for oxaliplatin at -361 ppm.27 The correspond-
ing 195Pt signal for the dichlorido precursor complex 2awith
PtN2Cl2 coordination was detected significantly upfield
at -644 ppm.
In 3a, all substituents (two amino and one methyl group)
of the cyclohexane ring are in an equatorial position; conse-
quently, protons at carbon atoms 1, 2, and 4 are axially
oriented, which can be proven by the Karplus relationship
for NMR spin-spin coupling constants (vicinal H-C-
C-H coupling constants are large at angles of 180 with
3JH,H ≈ 11-12 Hz, and small when the torsion angle is 60
with a coupling of around 5 Hz).
Indeed, large couplings of the axial proton H-1ax at 2.31
ppm with the neighboring protons H-2ax and H-6ax with
3JH,H=11.5Hz, and a small
3JH,H coupling toH-6eq of 4Hz
were detected (Figure 2), proving the equatorial position of
the amino substituent. The same holds true for proton H-2ax,
demonstrating the trans-configuration at C1-C2. In the case
of proton H-3ax, resonating at 0.89 ppm, a quartet with a
coupling constant of 12 Hz was found as a result of two
neighboring axial protons (H-2ax, and H-4ax) and addition-
ally the large geminal 3JH,H coupling to proton H-3eq. Axial
position ofH-4ax finally proves that themethyl group atC-4 is
equatorially oriented. Signal assignment of all remaining pro-
tons is based on two-dimensional 1H,1H- and 1H,13C corre-
lated NMR spectra. Of note is the diastereotopic splitting of
the methylene protons at C-3, C-4, and C-6, giving rise to six
single shift correlation signals in the 1H,13C NMR spectrum.
Synthesis and characterization of racemic 4-ethyl and 4-t-
butyl-1,2-cyclohexanediamine}oxalatoplatinum(II) com-
plexes 4 and 5 (all substituents at the cyclohexane ring
equatorial position, Scheme 1) were described recently.28
With the intention of further optimizing structure-activity
relationships, the platinum complex 3c, {(1R,2R,4S)-4-methyl-
1,2-cyclohexanediamine}oxalatoplatinum(II), exhibiting
Scheme 1. Synthesis of {(1R,2R,4R)-4-Methyl-1,2-cyclohex-
anediamine}oxalatoplatinum(II), 3aa
a (i) H2O2/HCOOH, (ii) MsCl/Py, NaN3, (iii) Pd/CaCO3, H2 (3 bar),
(iv) L-tartaric acid, (v) K2PtCl4/NaOH (0.25 M), and (vi) AgNO3,
potassium oxalate. Structures of 4-ethyl- and 4-t-butyl oxaliplatin
derivatives 4 and 5, synthesized as enantiomeric mixtures (all substitu-
ents at the cyclohexane ring in equatorial positions).
Figure 2. 1H and 195Pt (small insert) NMR spectrum of {(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II) 3a with NMR
numbering scheme and signal assignment. The oxalatoplatinum(II) fragment has been omitted for clarity.
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an axial methyl substituent at position 4 of the cyclohexane
ring, was synthesized (Supporting Information, Scheme S2).
Starting from enantiomerically pure (S)-citronellal, (S)-4-
methylcyclohexene was prepared, which was converted to
the corresponding diazide exhibiting trans-configuration at
C1/C2. After reduction, (1R,2R,4S)-4-methyl-1,2-cyclohex-
anediaminium L-tartrate, 1c, was obtained (diastereomeric
purity was proven by chiral HPLC in the form of the Cbz
derivative, Supporting Information, Figure S3). In analogy
to 3a and 3b, the oxalato complex 3c was synthesized and
characterized. Besides a distinctly different 195Pt chemical
shift (3c,-381 ppm; 3a,-365 ppm), the axial position of the
methyl group could be judged by comparison of 1H
(Supporting Information, Figure S4) and 13C NMR spectra
of 3a and 3c, respectively. As expected, the chemical shift
difference of protons H-1ax and H-2ax (Δδ= 0.27 ppm) in
3c is significantly bigger compared to 3a (Δδ = 0.08 ppm).
The same holds true for chemical shift differences of carbon
atoms C1 and C2 in 3c (Δδ = 4.9 ppm) and 3a (Δδ = 0.2
ppm). However, most indicative are the differences (shapes
and chemical shifts, compare Figures 2 and Supporting
Information, Figure S4) in the proton NMR spectra for 1H
resonances at C3, C4 and C5.
Cytotoxicity in Cancer Cell Lines and Structure-Activity
Relationships. Cytotoxicity of oxaliplatin and the here pre-
sented derivatives with equatorial alkyl substituents in posi-
tion 4 of the cyclohexane ring was compared by means of a
colorimetric microculture assay (MTT assay) in six human
cancer cell lines representing four tumor entities: ovarian
carcinoma (CH1), cervical carcinoma (HeLa), osteosarcoma
(U-2 OS), and colon carcinoma (HCT-15, HCT-116,
SW480), yielding IC50 values mostly in the low micromolar
or even submicromolar range (Table 1, Figure 3).
Oxaliplatin and the 4-methyl derivative 3a show quite
similar cytotoxic potencies in all six cell lines. Notably, 3a
is at least as active as oxaliplatin in four of them, except for
the two colon cancer cell lines HCT-116 and SW480. Gen-
erally, the (1R,2R,4R)-enantiomer 3a is by factors of 2-4more
cytotoxic than the (1S,2S,4S)-enantiomer 3b, indicating that
the well-known structure-activity relationship observed
Table 1. Cytotoxicity of Oxaliplatin Derivatives Compared to Oxaliplatin in Six Human Cancer Cell Lines
IC50 (μM)
a
compd CH1 HeLa HCT-15 HCT-116 SW480 U-2 OS
oxaliplatin 0.33( 0.09 0.35( 0.07 1.5( 0.6 0.38( 0.03 0.30( 0.08 0.72( 0.24
d-OHPb 1.0( 0.04 1.1( 0.4 4.4( 1.6 1.7( 0.1 1.3( 0.3 2.5 ( 0.7
3a 0.28( 0.09 0.21( 0.06 1.6 ( 0.1 0.81( 0.31 0.67( 0.31 0.71( 0.41
3b 0.69( 0.10 0.88( 0.38 4.6( 0.7 2.9( 0.7 2.3( 1.2 1.8( 0.6
3c 0.10( 0.01 0.24( 0.02 0.33( 0.07 0.32 ( 0.05 0.33( 0.14 0.52( 0.03
4 0.38( 0.08 0.66( 0.13 3.4( 1.0 1.6( 0.1 0.92( 0.30 4.0( 0.3
5 4.1( 0.8 11( 2 39( 3 31( 2 24( 3 24( 5
a 50% inhibitory concentrations in theMTT assay (96 h exposure). Values aremeans( standard deviations obtained from at least two (mostly three)
independent experiments. bd-OHP is the (1S,2S)-enantiomer of oxaliplatin.
Figure 3. Concentration-effect curves of ring-substituted oxaliplatin derivatives in comparison to oxaliplatin and its S,S analogue (d-OHP)
in CH1, HeLa, U-2 OS, HCT-15, HCT-116, and SW480 cells, obtained by the MTT assay (96 h exposure).
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with oxaliplatin and its (1S,2S)-enantiomer (d-OHP) also
applies to the alkyl-substituted derivatives. The other 4-methyl
derivative 3c (methyl substituent in axial position) is even
more cytotoxic than oxaliplatin in the majority of cell lines
and thus the most potent of the studied compounds, whereas
the racemic 4-ethyl derivative 4 yields IC50 values that are
mostly intermediate between those of 3a and 3b (with the
exception of U-2 OS cells).
In contrast, the IC50 values of the racemic 4-t-butyl
derivative 5 are on average an order of magnitude higher
than those of 4. These data support a previous study, which
showed that large alkyl substituents will result in a decrease
of cytotoxicity.29 Generally, the cytotoxicity profiles of these
compounds resemble each other, with CH1 and HeLa being
the most sensitive cell lines and HCT-15 being the least
sensitive cell line. Therefore, fundamental differences in the
underlying molecular mechanisms of action are unlikely.
The cytotoxic properties of compounds 3a and 3c were
also analyzed in cisplatin- and oxaliplatin-resistant cell
models derived from small cell lung (GLC4), ovarian cancer
(A2780), and colon cancer (HCT-116) (Table 2). Both highly
cisplatin-resistant cell models (GLC4/CDDP andA2780/cis)
were (comparable to oxaliplatin) significantly but very mod-
erately (up to 3.2-fold) cross-resistant to the novel deriva-
tives. The resistance of oxaliplatin-insensitive HCT-116 oxR
against the new derivatives was, as expected, more distinct
(up to 18.6-fold) as compared to that of cisplatin. Never-
theless, it was significantly weaker for both tested derivatives
(3a and 3c) as compared to oxaliplatin (36.7-fold).
InVivoAnticancerActivity.Anticancer activity in vivowas
investigated in the murine L1210 leukemia model. Com-
pounds were administered intraperitoneally on three con-
secutive days. A transient decrease of body weight to not less
than 85% was considered tolerable, and for each compound
the tolerable dose resulting in the highest increase in life span
(ILS) was considered optimal. Except for 5, which did not
allow dose escalation beyond 12mg/kg/day because of much
lower solubility, the maximum tolerated dose (MTD) was
reached for all compounds. The optimal dose in terms of
therapeutic efficacy is mostly identical with theMTD, except
for d-OHP, the (S,S)-analogue of oxaliplatin (Table 3).
Remarkably, a mere 50% dose increase over the MTD
(6 mg/kg/day) turned oxaliplatin in a 100% lethal com-
pound, indicating a steep lethality curve, whereas in the case
of the new derivatives, a 50% increase over the respective
MTD resulted only in 0-2 toxic deaths (in groups of six
animals each).With the exception of 3b, all compounds were
tolerated in at least 50% higher doses (9 mg/kg/day) than
oxaliplatin.
All compounds tested prolonged the survival of leukemic
mice with high statistical significance (p < 0.001) but to
different extents. The optimal therapeutic effect of the parent
compound oxaliplatin caused an increase in life-span (ILS)
by 152% and long-term survival of two animals (Table 3,
Figure 4A). Although in equal doses the efficacy of the
4-methyl derivative 3a is not higher than that of oxaliplatin,
the lower toxicity of this compound enables the application
of a higher dose, resulting in a clearly superior therapeutic
effect with as much as five long-term survivors and an ILS of
more than 200% (Figure 4B). Surprisingly, the analogous
complex 3c (with the 4-methyl substituent in axial instead of
equatorial position) causes an ILS of only 122%. Thus, this
compound is much less active than 3a and even somewhat
less active than oxaliplatin despite a cytotoxic potency super-
ior to all other compounds studied in vitro. The 4-ethyl
derivative 4 is also slightly less effective than oxaliplatin and
causes an ILS of 129%, with one long-term surviving animal
at the optimal dose. However, this compound is a racemic
mixture, and improved therapeutic efficacy might still be
expected from the pure (1R,2R,4R)-enantiomer. The lower
efficacy of (1S,2S)-enantiomers is confirmed by data obtained
with d-OHP and 3b, which are no more than half as effective
as oxaliplatin and 3a, respectively. Finally, further increasing
the size of the substituent to t-butyl (compound 5) results in a
tremendous loss of activity in applicable doses, which par-
allels the structure-activity relationships observed in vitro.
A synopsis of in vitro and in vivo data reveals that small
alkyl substituents (methyl, perhaps also ethyl) on the cyclo-
hexane ring result in an optimum with respect to the ther-
apeutic index mainly due to a higher tolerability than
unsubstituted oxaliplatin and a higher activity than deriva-
tives with larger substituents. However, the geometric orien-
tation (axial vs equatorial) of the substituent obviously
plays a decisive role, having opposite effects on cytotoxicity
in vitro and efficacy in vivo. Apart from that, structure-
activity relationships in vitro and in vivo nicely parallel each
other within the 4-substituted oxaliplatin derivatives, but
this aberrant example demonstrates that caution should be
exercised when selecting candidate compounds for drug
development on the basis of in vitro data. The L1210
leukemia model employed may seem remote from the actual
clinical indication of oxaliplatin, i.e. colorectal cancer, but it
should be called in mind that it was one of the few tumor
models in which the promising activity of oxaliplatin was
originally recognized and therefore proved particularly valu-
able in this context.30,31 Nevertheless, further evaluation of
the compounds will require additional models, in particular,
solid tumors.
As the cytotoxicity profiles of the studied compounds
argue against fundamental differences in the mode of action,
the reasons for the differences in therapeutic index and the
favorable cross-resistance patterns may be found in the
combination of characteristics such as lipophilicity and
bulkiness and their subtle consequences for drug transport,
biotransformation, and interactions with DNA as well as
DNA repair systems.
Comparing both methyl derivatives 3a (equatorial methyl
group) and 3c (axial methyl group), it is remarkable that 3c is
Table 2. Cytotoxicity of Oxaliplatin Derivatives Compared to Oxaliplatin in Cisplatin- And Oxaliplatin-Resistant Human Cancer Cell Models
IC50 (μM)
a
compd GLC4 GLC4/CDDP -fold resistance A2780 A2780/cis -fold resistance HCT116 HCT116 oxR -fold resistance
cisplatin 1.7( 0.5 18.0 10.6 1.8( 0.2 >10 >5 4.7( 0.1 7.3( 0.1 1.6
oxaliplatin 0.6( 0.2 1.2( 0.3 2.0 0.4( 0.2 0.7( 0.4 1.8 0.6( 0.1 22.0( 0.1 36.7
3a 0.8( 0.1 2.1( 0.1 2.6 0.5( 0.1 1.6 ( 0.8 3.2 1.5( 0.1 11.7( 0.1 7.8
3c 0.3( 0.2 0.6( 0.1 2.0 0.2( 0.1 0.5( 0.3 2.5 0.5( 0.1 9.3( 0.1 18.6
a 50% inhibitory concentrations in theMTT assay (72 h exposure). Values aremeans( standard deviations obtained from at least two (mostly three)
independent experiments.
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equipped with a higher cytotoxicity in vitro, but in parallel
showing a lower anticancer activity in vivo. Differences
between 3a and 3c in the cellular accumulation and DNA
adduct formation are expected to be very similar in vitro and
in vivo. Nevertheless, one might assume the existence of
interacting factors like altered transport by drug uptake and/
or efflux pumps whichmight impact on the pharmacological
characteristics of these stereoisomeric complexes in vivo but
not in vitro. The identification of these interacting factors is a
matter of ongoing investigations.
Conclusions
In this study, we successfully developed an oxaliplatin
derivative with enhanced antitumor activity compared to
the parental drug by introducing a small alkyl substituent
on the cyclohexane ring in equatorial position. Using the
L1210murine leukemia model, the highest anticancer activity
was proven for {(1R,2R,4R)-4-methyl-1,2-cyclohexanedi-
amine}oxalatoplatinum(II), resulting in both increased life
span and enhanced long-term survival. Although in vitro this
compound is not consistentlymore cytotoxic thanoxaliplatin,
the better tolerability enables application of higher doses,
resulting in enhanced efficacy in vivo. Considering that
adverse effects are a central problem of clinical oxaliplatin
application, the evaluation of the new derivative in
(pre)clinical studies is highly desirable. These studies should
primarily focus on colorectal cancer, where oxaliplatin is used
as therapeutic standard, but also on other tumors recently
suggested to be sensitive against this third-generation plati-
num compound like certain leukemias32 or esophago-gastric
cancer.33
Experimental Section
If necessary, the reactions were carried out in dry solvents and
under argonatmosphere. Potassium tetrachloridoplatinate(II) was
obtained from JohnsonMatthey (Switzerland). All other chemicals
obtained from commercial suppliers were used as received and
were of analytical grade. Water was prior to use doubly distilled.
The synthetic procedures were carried out in light protected
environment when platinum complexes were involved. 1H, 13C,
15N, 195Pt, and two-dimensional COSY NMR spectra were re-
corded with a Bruker Avance DPX 400 instrument (Ultrashield
Magnet) at 400.13 MHz (1H) and 100.63 MHz (13C) or with a
Bruker Avance III 500 MHz NMR spectrometer at 500.32 (1H),
125.81 (13C), 107.55 (195Pt), and 50.70 MHz (15N) in DMF-d7,
D2O, or CDCl3 at 298 K.
15N chemical shifts were referenced
relative to external NH4Cl, whereas
195Pt chemical shifts were
referenced relative to external K2[PtCl4]. HPLC analysis was
carried out using aDionex Summit system. The sample concentra-
tion was 1.0mg/mL, with an injection volume of 10 μL introduced
onto a Chiralcel OD column (250 mm  4.6 mm) protected by a
guard column (50 mm  4.6 mm) at 5 C. The flow rate of the
mobile phase (hexane:i-propyl alcohol 9:1) was 1mL/min.Melting
points were determined with a B€uchi B-540 apparatus and are
Table 3. Tolerability and Efficacy of Intraperitoneal Treatment with Oxaliplatin Derivatives Compared to Oxaliplatin in L1210 Leukemia-Bearing
Mice (Therapeutic Effects at the Respective Optimum Dose Are Marked in Bold Type)
compd dose (mg/kg/day) min body weight (%) toxic deaths ILS (%)a long-term survivorsb
oxaliplatin 9 6/6 0/6
6 (MTD)c 93.2 0/6 152 2/6
4.5 91.3 0/6 89 1/6
3 94.1 0/6 94 1/6
d-OHP 12 1/6 0/6
9 (MTD)c 85.9 0/6 63 0/6
6 93.1 0/6 73 1/6
4.5 93.6 0/6 26 0/6
3a 12 2/6 4/6
9 (MTD)c 88.6 0/6 > 200 5/6
6 97.5 0/6 119 0/6
4.5 94.6 0/6 84 1/6
3 97.3 0/6 90 0/6
3b 9 1/6 0/6
6 (MTD)c 92.0 0/6 103 1/6
4.5 93.4 0/6 68 2/6
3 97.9 0/6 68 1/6
3c 12 2/6 1/6
9 (MTD)c 86.4 0/6 122 2/6
6 87.3 0/6 78 1/6
4.5 87.9 0/6 111 2/6
4 12 83.2 0/6 144 2/6
9 (MTD)c 89.9 0/6 129 1/6
6 93.6 0/6 89 0/6
3 98.4 0/6 61 0/6
5 12 100.0 0/6 33 0/6
6 100.0 0/6 25 0/6
3 98.5 0/6 17 0/6
a Increase in life span compared to untreated controls, based onmedian survival; all values indicate life prolongation with high statistical significance
(p< 0.001). bAnimals with ILS > 200% without any signs of leukemia. cMaximum tolerated dose.
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uncorrected. Electrospray ionization mass spectra were recorded
on aBruker esquire3000 in positive ionmode. Elemental analyses of
prepared compounds were carried out on a Perkin-Elmer 2400
CHN elemental analyzer or a Carlo Erba microanalyzer at the
Microanalytical Laboratory of the University of Vienna and are
within (0.4% of the calculated values, confirming their g95%
purity. Silica gel (Polygram SIL G/UV254) was used for thin layer
chromatography.
(SP-4-3)-[(1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine- K2N,
N0][ethanedioato(2-)-K2O1,O2]platinum(II) 3a. AgNO3 (167 mg,
0.98 mmol) was added to a suspension of (SP-4-3)-dichlorido-
[(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine-κ2N,N0]platinum-
(II) 2a (200 mg, 0.5 mmol) in water (3 mL). The reaction mixture
was stirred for 24 h at room temperature, the precipitated silver
chloride was filtered off, and an in situ prepared solution of
potassium oxalate from oxalic acid dihydrate (61 mg, 0.48 mmol)
andKOH(0.96mL, 0.5M, 0.48mmol) inwater (2mL)was added
to the diaqua complex. The reactionmixturewas stirred for 24 h at
room temperature, the solvent was removed in vacuum, and the
pure white complex was obtained after recrystallization in water
(1 mL). The product was filtered off and dried under reduced
pressure over P4O10. Yield: 0.82 mg (39%), mp 282-290 C
(decomp). Elemental analysis, Found: C, 26.05; H, 3.65; N,
6.55. Calcd for C9H16N2O4Pt: C, 26.28; H, 3.92; N, 6.81. MS
(ESIþ) m/z 434 [M þ Na]þ. 1H NMR in D2O: δ = 0.85 (dq,
3JH,H =
2JH,H = 13 Hz,
3JH,H = 3.5 Hz, 1H, H-5ax), 0.86 (d,
3JH,H = 6.5 Hz, 3H, H-7), 0.98 (q,
3JH,H=
2JH,H = 12 Hz, 1H,
H-3ax), 1.29 (dddd, JH,H=12.5Hz, JH,H=12.5Hz, JH,H=12.0
Hz, JH,H=3.5Hz, 1H,H-6ax), 1.37 (m, 1H,H-4ax), 1.51 (m, 1H,
H-5eq), 1.88-2.00 (mþm, 2H, H-3eq, H-6eq), 2.31 (dt, 3JH,H=
11.5 Hz, 3JH,H = 4.0 Hz, 1H, H-1ax), 2.39 (dt,
3JH,H = 11.5 Hz,
3JH,H = 4.0 Hz, 1H, H-2ax).
13C NMR in D2O: δ= 20.0 (C-7),
30.6 (C-6), 30.9 (C-4), 32.2 (C-5), 39.5 (C-3), 62.0 (C-2), 62.2 (C-1),
168.3 (COO). 195Pt NMR in D2O: δ= -365.
(SP-4-3)-[(1S,2S,4S)-4-Methyl-1,2-cyclohexanediamine- K2N,
N0][ethanedioato(2-)-K2O1,O2]platinum(II) 3b. Following the
same procedure as described for 3a, complex 3b was obtained
from (SP-4-3)-dichlorido[(1S,2S,4S)-4-methyl-1,2-cyclohexane-
diamine-κ2N,N 0]platinum(II) 2b (200 mg, 0.5 mmol). Yield: 0.82
mg (38%),mp275-280 C(decomp). Elemental analysis,Found:
C, 26.07; H, 3.66; N, 6.83. Calcd for C9H16N2O4Pt: C, 26.28; H,
3.92; N, 6.81. MS (ESIþ) m/z 434 [M þ Na]þ. 1H NMR in D2O:
δ=0.85 (dq, 3JH,H=
2JH,H=13Hz,
3JH,H=3.5Hz, 1H,H-5ax),
0.86 (d, 3JH,H=6.5Hz, 3H,H-7), 0.97 (q,
3JH,H=
2JH,H=12Hz,
1H,H-3ax), 1.28 (dddd, JH,H= 12.5Hz, JH,H= 12.5Hz, JH,H=
12.0Hz,JH,H=3.5Hz, 1H,H-6ax), 1.36 (m,1H,H-4ax), 1.50 (m,
1H, H-5eq), 1.88-2.00 (m þ m, 2H, H-3eq, H-6eq), 2.30 (dt,
3JH,H= 11.5 Hz,
3JH,H= 4.0 Hz, 1H, H-1ax), 2.38 (dt,
3JH,H=
11.5Hz, 3JH,H=4.0Hz, 1H,H-2ax).
13CNMR inD2O: δ=20.0
(C-7), 30.6 (C-6), 30.9 (C-4), 32.2 (C-5), 39.5 (C-3), 62.0 (C-2),
62.2 (C-1), 168.3 (COO). 195Pt NMR in D2O: δ=-365.
(SP-4-3)-[(1R,2R,4S)-4-Methyl-1,2-cyclohexanediamine- K2N,N0]-
[ethanedioato(2-)-K2O1,O2]platinum(II) 3c. (SP-4-3)-{Dichlorido-
[(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine-κ2N,N 0]platinum(II)}
(1.767g, 4.48mmol) was suspended in 80mLofwater anda solution
of AgNO3 (1.462 g; 8.60 mmol) in 10 mL of water was added. The
suspension was stirred for 24 h at room temperature. The AgCl
formedwas filtered off with aG4 glass sinter filter with an additional
MNGF3filter.Theclear, slightly yellowish solutionwas treatedwith
conditioned basic ion-exchange resin IRA402 for 24 h at room
temperature (shaking). [Conditioning of IRA402: 150 g of IRA402
chloride formwasstirredwith2MNaOH(400mL) for30min.Then
the resinwaswashedwithdeionizedwater until achievingneutral pH
followed by washing with distilled water twice.] The ion-exchange
resin was separated from the solution by decantation and washed
withwater three times.The combinedaqueous solutionswere filtered
through a G4 glass sinter filter, and oxalic acid dihydrate (0.565 g,
4.48mmol) was added. Themixture was put into a round flask, and
the volume was reduced to ca. 80 mL within 3 h, whereupon the
liquid became cloudy. The latter was kept at room temperature for
12 h and was further reduced to ca. 40 mL. A white solid formed
whichwas finally filteredwithaG4glass sinter filter after 1h,washed
with water twice, and dried in vacuum over P4O10. Yield: 0.534 g
(29%). Elemental analysis, Found: C, 26.07; H, 3.88; N, 6.66. Calcd
for C9H16N2O4Pt: C, 26.28; H, 3.92; N, 6.81.
1HNMR inD2O: δ=
0.84 (d, 3JH,H=7.5Hz, 3H,H-7), 1.22-1.55 (mþmþmþm,4H,
H-5eq, H-5ax, H-3ax, H-6ax) 1.71-1.90 (m þ m þ m, 3H, H-3eq,
H-6eq, H-4eq), 2.24 (dt, 3JH,H = 12.0 Hz,
3JH,H = 4.5 Hz, 1H,
H-1ax), 2.51 (dt, 3JH,H=12.0 Hz,
3JH,H = 4.0 Hz, 1H, H-2ax).
13CNMRinD2O:δ=16.7 (C-7), 26.4 (C-6), 27.0 (C-4), 29.3 (C-5),
37.2 (C-3), 57.8 (C-2), 62.7 (C-1), 168.3 (COO). 195PtNMR inD2O:
δ=-381.
Cell Lines and Culture Conditions. CH1 (ovarian carcinoma,
human) cells were kindly provided by Lloyd R. Kelland (CRC
Centre for Cancer Therapeutics, Institute of Cancer Research,
Sutton, UK). HeLa (cervical carcinoma, human) and U-2 OS
(osteosarcoma, human) cells were donated by Thomas Czerny
(Institute of Genetics, University of VeterinaryMedicine Vienna,
Austria). SW480, HCT116, and HCT15 (all colon carcinoma,
human) cellswere kindly provided byBrigitteMarian (Institute of
Cancer Research,Medical University of Vienna, Austria). In addi-
tion, cellmodels comprisingaparental drug-sensitive and respective
cisplatin-oroxaliplatin-resistant sublinewereused.GLC4small cell
lung cancer cells together with cisplatin-resistant GLC4/CDDP
cells were kindly supplied by Elisabeth de Vries, University of
Groningen. The ovarian carcinoma cell line A2780 together with
the cisplatin-resistant sublineA2780/cis were obtained fromSigma.
The oxaliplatin-resistant subline HCT-116 oxR was established by
stepwise drug selection of HCT-116 colon cancer cells.
GLC4 and A2780 cell lines and derivatives were grown in
RPMI1680mediumwith 10% fetal bovine serum.All other cells
Figure 4. Kaplan-Meier plots showing the survival (days after
tumor implantation) of L1210 leukemia-bearing mice treated in-
traperitoneally with different doses of oxaliplatin or 3a in compar-
ison to untreated controls, in groups of six animals each. Note that
mortality in animals treated with 9 mg/kg/day oxaliplatin is drug-
related in all cases (A), whereas the same dose of 3a results in long-
term survival of five animals (B).
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were cultured in complete culture medium, i.e., Minimal Essen-
tial Medium (MEM) supplemented with 10% heat-inactivated
fetal bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine,
and 1% nonessential amino acids (100) (all purchased from
Sigma-Aldrich). Cultures were maintained at 37 C in a humid-
ified atmosphere containing 5% CO2 and 95% air.
Cytotoxicity Tests in Cancer Cell Lines. Antiproliferative
activity was determined by a colorimetric microculture assay
(MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphen-
yl-2H-tetrazolium bromide). For this purpose, cells were har-
vested from culture flasks by trypsinization and seeded in
100-μL aliquots into 96-well microculture plates (Iwaki/Asahi
Technoglass) in the following densities: 1.5 103 (CH1, HeLa),
2.0  103 (GLC4 cell model), 2.5  103 (SW480, HCT-116 cell
model,HCT-15), and 3.2 103 (U2OS,A2780 cellmodel) viable
cells/well. Cells were allowed to settle and resume adherent
growth in drug-free complete culture medium for 24 h, followed
by the addition of dilutions of the test compounds in 100 μL/
well complete culture medium and incubation for 96 h. In
experiments involving drug-resistance models, the incubation
time was 72 h. At the end of exposure, medium was replaced by
100 μL/well RPMI 1640 medium (supplemented with 10%
heat-inactivated fetal bovine serum and 4mML-glutamine) plus
20 μL/well MTT solution in phosphate-buffered saline (5 mg/
mL). After incubation for 4 h, medium was removed and the
formazan product formed by viable cells was dissolved in
DMSO (150 μL/well). Optical densities at 550 nm were mea-
sured with a microplate reader (Tecan Spectra Classic). The
quantity of viable cells was expressed in terms of T/C values by
comparison to untreated controls, and 50% inhibitory concen-
trations (IC50) were calculated from concentration-effect
curves by interpolation. Evaluation is based on means from
at least two (mostly three) independent experiments, each
comprising six replicates per concentration level.
Antileukemic Activity in Vivo. Animal experiments were
performed in accordance with the European Community
Guidelines for the use of experimental animals in the animal
facility at the Cancer Research Institute, Slovak Academy of
Sciences, Bratislava, Slovak Republic. L1210 murine leukemia
cells (1 105) were injected in a volume of 0.5 mL into DBA/2J
mice (weighing 18-22 g) intraperitoneally on day 0. The test
compounds were administered intraperitoneally in a volume of
0.5 mL aqua ad injectionem per mouse per day in a split-dose
regimen (days 1, 2, and 3 after implantation of cells) to groups of
six animals per dose. Toxicity of the test compounds was
monitored by daily observation of animals and registration of
their body weight. Therapeutic efficacy of the test compounds
was monitored by recording the lengths of survival of experi-
mental mice compared to untreated control animals. The ex-
periment was terminated after the 3-fold of the survival time of
untreated controls, and animals experiencing an increase in life
span of more than 200% without any signs of leukemia were
considered long-term survivors. The absence of malignant dis-
ease in the abdominal cavity was confirmed by dissection.
Statistical significance of survival data was calculated using
the unpaired t test.
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Supporting Information Available: Figure with the crystal
structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in
a DNA dodecamer duplex; scheme with the separation of
racemic (1R,2R,4R/1S,2S,4S)-4-methyl-1,2-cyclohexanedia-
mine and with structures of CBz analogues used for chiral
HPLC analysis, figure with the confirmation of enantiomeric
purity of (1R,2R,4R)- and (1S,2S,4S)-4-methyl-1,2-cyclohex-
anediamine by chiral HPLC, scheme with the synthesis
of {(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine}oxalato-
platinum(II), figure with the confirmation of diastereomeric
purity of (1R,2R,4S)-4-methyl-1,2-cyclohexanediamine after
transformation into the CBz-derivative, figure with 1H- and
195Pt NMR spectra of {(1R,2R,4S)-4-methyl-1,2-cyclohexanedi-
amine}oxalatoplatinum(II) 3c, synthesis and characterization
of (S)-4-methylcyclohexene, 4-methyl-1,2-cyclohexanediaminium
tartrates 1a-1c, (SP-4-3)-dichlorido[4-methyl-1,2-cyclohexanedia-
mine-κ2N,N0]platinum(II) complexes 2a-2c, and N,N0-bis-
(benzyloxycarbonyl)-4-methyl-1,2-cyclohexanedicarbamates 6
and 7. This material is available free of charge via the Internet
at http://pubs.acs.org.
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Figure S1. Crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA 
dodecamer duplex. 
Protein Data Bank, PDB ID: 1IHH, Spingler, B., Whittington, D.A., Lippard, S.J. 2001, 2.4 
Angstrom Crystal Structure of an Oxaliplatin 1,2-d(GpG) Intrastrand Cross-Link in a DNA 
Dodecamer Duplex, Inorg. Chem., 40, 5596. 
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Scheme S1. Separation of the racemic mixture of (1R,2R,4R)- and (1S,2S,4S)-4-methyl-1,2-
cyclohexanediamine via recrystallization with the L- or D-tartrate and conversion of the 
diaminium tartrates into the UV-active CBz analogs used for chiral HPLC analysis.  
 
 
 
 
 
Figure S2. Confirmation of enantiomeric purity of (1R,2R,4R)- and (1S,2S,4S)-4-methyl-1,2-
cyclohexanediamine after transformation into the CBz-derivatives by chiral HPLC.  
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Scheme S2. Synthesis of {(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine}oxalato-
platinum(II), 3c. (i) Me(PPh3)3Br/BuLi, (ii) trans-WOCl2(OAr)2 (Ar = 2,6-dibromophenyl)/ 
tetraethyllead, (iii) NaN3/Mn(OAc)3, (iv) Pd/CaCO3, H2 (10 bar), (v) L-tartaric acid, (vi) 
K2PtCl4/NaOH and (vii) AgNO3, basic ion exchanger, oxalic acid.  
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Figure S3. Confirmation of diastereomeric purity of (1R,2R,4S)-4-methyl-1,2-
cyclohexanediamine after transformation into the CBz-derivatives by chiral HPLC (upper 
curve, mixture of (1R,2R,4S)- and (1S,2S,4S)-isomers; lower curve, pure (1R,2R,4S)-isomer. 
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Figure S4. 1H- and 195Pt (small insert) NMR spectrum of {(1R,2R,4S)-4-methyl-1,2-
cyclohexanediamine}oxalatoplatinum(II) 3c with NMR numbering scheme and signal 
assignment, the oxalatoplatinum(II) fragment has been omitted for clarity. 
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Synthesis of (S)-4-Methylcyclohexene1 
(S)-4,8-Dimethyl-l,7-nonadiene  
A suspension of methyltriphenylphosphonium bromide (22.9 g, 64.1 mmol) in absolute 
tetrahydrofuran (400 mL) was filled into a three-necked flask under inert conditions and 
cooled to -20°C. Butyllithium (1.60 M in hexane; 38.0 mL, 60.8 mmol) was added via 
syringe. The orange mixture was stirred for 30 min. at room temperature and then cooled to 
-78°C. Thereafter, (S)-3,7-dimethyl-6-octenal ((S)-citronellal; 11.0 mL, 60.7 mmol) was 
added slowly, keeping the temperature low. The mixture was stirred for 1 h at -78°C and was 
then allowed to warm up slowly to room temperature. Acetone (10 mL) was added and the 
reaction mixture was stirred for 30 min to quench the excess of reagent. Eventually, the 
mixture was added to hexane (800 mL) and filtered. From the filtrate the solvent was removed 
with a rotary evaporator at reduced pressure, the solid formed was filtered off and washed 
with hexane. Again, hexane was removed using a rotary evaporator and the raw product was 
distilled under vacuum to afford the diene as a colorless liquid. Yield: 6.56 g (71%). 1H NMR 
in CDCl3: δ = 0.90 (d, 3J=6.5 Hz, 3H), 1.12-1.21 (m, 1H), 1.33-1.41 (m, 1H), 1.48-1.57 (m, 
1H), 1.62 (s, 3H), 1.70 (s, 3H), 1.87-2.13 (m, 4H), 4.97-5.04 (m, 2H), 5.12 (t, 1H), 5.74-5.86 
(m, 1H).  
 
trans-Dichlorobis(2,6-dibromphenoxy)oxotungsten(VI) 
A mixture of tungsten(VI) oxychloride (1.71 g, 5.00 mmol) and 2,6-dibromphenol (2.52 g, 
10.0 mmol) in absolute toluene (25 mL) was heated at reflux for 1 h under argon. After the 
mixture was cooled down to room temperature, the solvent was removed under vacuum. The 
residue was stirred with absolute dichloromethane (100 mL) under argon for 10 min. The 
                                                 
1
 Nugent, W. A.; Feldman, J.; Calabrese, J. C. Practical Catalyst for Cyclic Metathesis. 
Synthesis of Functional and/or Enantiopure Cycloalkenes. J. Am. Chem. Soc. 1995, 117, 
8992–8998. 
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solution was filtered inertly and filled into a sidearm round flask. Thereafter the solvent was 
removed in vacuum and the resulting amorphous, dark-red solid was stored under argon. The 
flask was directly used for the next reaction step. 
 
(S)-4-Methylcyclohexene 
trans-Dichlorobis(2,6-dibromphenoxy)oxotungsten(VI) was dissolved in dry 
trichlorobenzene (180 mL) under argon in a Schlenk flask, and (S)-4,8-dimethyl-l,7-
nonadiene (31.5 g, 228 mmol), as well as tetraethyllead (50% solution in xylenes, 10g, 15 
mmol) were added. The dark red mixture was heated up to 90°C, whereby a color change 
from deep-red to dark-blue, as well as a gas evolvement were observed. The mixture was kept 
at 90° for 2 h. After cooling down to room temperature, the solution was stirred shortly with 
silica (10 g) and filtered; a colorless liquid was obtained. Distillation at 97-120 °C produced a 
crude product containing about 10% of dissolved xylenes, which did not with subsequent 
transformations of the product. Yield: 19,5 g with about 10% xylenes (about 17,5 g of the 
product, 89 % ). 1H NMR in CDCl3: δ = 0.97 (d, 3J=6.5 Hz, 3H), 1.17-1.30 (m, 1H), 1.59-1.74 
(m, 3H), 2.00-2.14 (m, 3H), 5.64-5.71 (m, 2H).  
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(1R,2R,4R)-4-Methyl-1,2-cyclohexanediaminium L-tartrate 1a 
A mixture of 4-methyl-trans-(±)-1,2-cyclohexanediazide (2.1 g, 14.0 mmol) and palladium 
on CaCO3 (Lindlar’s catalyst, 5% Pd, 420 mg) in dry ethanol (30 mL) was stirred for 24 h 
under hydrogen atmosphere (3 bar). The catalyst was filtered off, the volume of the solvent 
was reduced to 2/3 and 4-methyl-trans-1,2-cyclohexanediaminium L-tartrate 1a/1a’ was 
precipitated by addition of L-tartaric acid until a pH of 7 was reached. The diaminium salt was 
filtered off, washed with diethyl ether (2 × 50 mL), and dried in vacuum. Yield 1.23 g (35%). 
A suspension of 4-methyl-1,2-trans-cyclohexanediaminium L-tartrate 1a/1a’ (3.0 g) in 
absolute ethanol (50 mL) was refluxed for 15 min, then water was added dropwise to obtain a 
clear solution. The solution was allowed to cool down to room temperature and was kept in 
the refrigerator for 12 h at 4 °C. The enantiomer 1a was filtered off and dried in vacuum. 
Yield: 0.54 g (36%), m.p. 258–260 °C, [ ]D 
 20 α = +12 (c 0.5, acetone). Elemental analysis, found: 
C, 47.28; H, 8.04; N, 10.34. Calcd for C11H22N2O6: C, 47.47; H, 7.97; N, 10.07. MS (ESI+) 
m/z 129 [M+H]+. 1H NMR in D2O: δ = 0.85 (d, 3JH,H = 6.5 Hz, 3H, H-7), 0.99 (m, 1H, H-5), 
1.15 (m, 1H, H-3), 1.41–1.58 (m, 2H, H-4, H-6), 1.71 (m, 1H, H-5`), 1.98–2.10 (m, 2H, H-6`, 
H-3`), 3.20–3.38 (m, 2H, H-1, H-2) 4.24 (s, 2H, CHOH). 13C NMR in D2O: δ = 20.7 (C-7), 
29.5 (C-6), 30.2 (C-4), 31.5 (C-5), 37.6(C-3), 52.4 (C-1), 52.5 (C-2), 74.2 (CHOH), 178.9 
(COO). 
 
(1S,2S,4S)-4-Methyl-1,2-cyclohexanediaminium D-tartrate 1b 
Following the same procedure as described for 1a, compound 1b was synthesized. Yield: 
0.86 g (57%), m.p. 257–259 °C, [ ]D 
 20 α = -12 (c 0.5, acetone). Elemental analysis, found: C, 
47.51; H, 7.79; N, 9.84. Calcd for C11H22N2O6: C, 47.47; H, 7.97; N, 10.07. MS (ESI+) 
m/z 129 [M+H]+. 1H NMR in D2O: δ = 0.85 (d, 3JH,H = 6.5 Hz, 3H, H-7), 0.98 (m, 1H, H-5), 
1.14 (m, 1H, H-3), 1.43–1.53 (m, 2H, H-4, H-6), 1.71 (m, 1H, H-5`), 2.00–2.07 (m, 2H, H-6`, 
H-3`), 3.20–3.35 (m, 2H, H-1, H-2) 4.23 (s, 2H, CHOH). 13C NMR in D2O: δ = 20.7 (C-7), 
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29.6 (C-6), 30.3 (C-4), 31.5 (C-5), 37.7 (C-3), 52.4 (C-1), 52.5 (C-2), 74.2 (CHOH), 178.9 
(COO). 
 
(1R,2R,4S)-4-Methyl-1,2-cyclohexanediaminium L-tartrate 1c 
(S)-4-Methylcyclohexene (10 g, 0.105 mol) and trifluoroacetic acid (120 mL) were added to 
a suspension of manganese acetate dihydrate (83.5 g, 0.31 mol) and sodium azide (34 g, 0.52 
mol) in acetonitrile (1200 mL) under argon at -20°C. The reaction mixture was stirred for 3 h 
at -20°C and for 12 h at room temperature. Thereafter, Na2S2O5 (10%, 300 mL) was added till 
the solution became clear. The intermediate diazide was extracted with petroleum ether (4 × 
150 mL), washed with saturated Na2CO3 solution (2 × 100 mL) and brine (2 × 100 mL) and 
dried over Na2SO4. The solvent was removed in vacuum and the resulting oil was sissolved in 
90 mL of ethanol. One third of the intermediate (30 mL of solution) was mixed with Lindlar 
catalyst (Pd on CaCO3, 5% Pd, 1.6 g) and filled into an autoclave, which was then evacuated 
and pressurized with 10 bar of hydrogen. The suspension was stirred for 24 h at room 
temperature. The catalyst was filtered off and the product was precipitated by addition of a 
20% stoichiometric excess of L-tartaric acid (6.3 g, 0.042 mol) in ethanol. The salt was 
filtered off, washed with diethyl ether (2 × 30 mL) and dried in vacuum. The product was 
recrystallyzed twice from a ethanol/water (1/1) mixture. The other two parts of the diazide 
intermediate were treated in the same way. Yield: 8.77 g (30%), elemental analysis, found: C, 
47.49; H, 8.13; N, 10.34.Calcd for C11H22N2O6: C, 47.47; H, 7.97; N, 10.07. 1H NMR in D2O: 
δ = 0.90 (d, 3JH,H = 7.5 Hz, 3H, H-7), 1.36-1.46 (m, 1H, H-5), 1.58 (m, 1H, H-5`), 1.65-1.81 
(m, 3H, H-3, H-6, H-3`), 1.84-2.10 (m, 2H, H-6`,H-4), 3.36 (m, 1H, H-1), 3.54 (m, 1H, H-2), 
4.24 (s, 2H, CHOH). 13C NMR in D2O: δ = 17.5 (C-7), 23.7 (C-6), 25.4 (C-4), 27.4 (C-5), 
33.5 (C-3), 48.3 (C-2), 50.9 (C-1), 73.8 (CHOH), 178.5 (COO). 
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(SP-4-3)-Dichlorido[(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine-к²N,N`]platinum(II) 
2a 
A solution of (1R,2R,4R)-4-methyl-1,2-cyclohexanediaminium L-tartrate (0.3 g, 1.1 mmol) 
in water (10 mL) was mixed with a solution of K2PtCl4 (0.45 g, 1.1 mmol) in water (15 mL). 
The pH of the reaction mixture was kept at ca. 7 over 24 h by addition of NaOH solution 
(0.25 M). The yellow product was filtered off, washed with HCl (2M, 2 × 5 mL) and water 
(3 ×10 mL), and dried in vacuum over P2O5. Yield: 0.33 g (78%), m.p. > 400 °C (decomp.). 
Elemental analysis, found: C, 21.41; H, 3.93; N, 6.89. Calcd for C7H16N2PtCl2 : C, 21.33; H, 
4.09; N, 7.11. MS (ESI+) m/z 417 [M+Na]+, [ ]D 
 20 α = +100 (c = 0.5, DMSO). 1H NMR in DMF-
d7: δ = 0.84-0.97 (m, 1H, H-5ax; d, 3JH,H = 6.5 Hz, 3H, H-7), 1.22 (q, 3JH,H = 2JH,H = 12 Hz, 
1H, H-3ax), 1.41 (m, 1H, H-4ax), 1.48-1.60 (m+m, 2H, H-6ax, H-5eq), 1.99-2.11 (m+m, 2H, 
H-3eq, H-6eq), 2.46-2.66 (m+m, 2H, H-1ax, H-2ax), 5.01 (m, 2H, N1-H/N2-H), 5.58 (m, 2H, 
N1-H/N2-H). 13C NMR in DMF-d7: δ =20.6 (C-7), 31.0 (C-6), 31.5 (C-4), 33.0 (C-5), 40.2 (C-
3), 63.2 (C-2), 63.4 (C-1). 15N NMR in DMF-d7: δ = –21.3. 195Pt NMR in DMF-d7: δ = –644. 
 
(SP-4-3)-Dichlorido[(1S,2S,4S)-4-methyl-1,2-cyclohexanediamine-к²N,N`]platinum(II) 
2b 
Following the same procedure as described for 1b, complex 2b was obtained from 
(1S,2S,4S)-4-methyl-1,2-cyclohexanediaminium D-tartrate (0.3 g, 1.1 mmol). Yield: 0.35 g 
(83%), m.p. > 400 °C (decomp.). Elemental analysis, found: C, 21.23; H, 3.87; N, 6.89. Calcd 
for C7H16N2PtCl2 : C, 21.33; H, 4.09; N, 7.11. MS (ESI+) m/z 417 [M+Na]+, [ ]D 
 20 α = -100 (c = 
0.5, DMSO). 1H NMR in DMF-d7: δ = 0.84-0.97 (m, 1H, H-5ax; d, 3JH,H = 6.5 Hz, 3H, H-7), 
1.22 (q, 3JH,H = 2JH,H = 12 Hz, 1H, H-3ax), 1.41 (m, 1H, H-4ax), 1.48-1.60 (m+m, 2H, H-6ax, 
H-5eq), 1.99-2.11 (m+m, 2H, H-3eq, H-6eq), 2.46-2.66 (m+m, 2H, H-1ax, H-2ax), 5.00 (m, 
2H, N1-H/N2-H), 5.58 (m, 2H, N1-H/N2-H). 13C NMR in DMF-d7: δ =20.6 (C-7), 31.0 (C-6), 
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31.5 (C-4), 33.0 (C-5), 40.2 (C-3), 63.2 (C-2), 63.4 (C-1). 15N NMR in DMF-d7: δ = –21.4. 
195Pt NMR in DMF-d7: δ = –644. 
 
(SP-4-3)-Dichlorido[(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine-к²N,N`]platinum(II) 
2c 
Potassium tetrachloroplatinate (8.255 g, 0.02 mol) was dissolved in distilled water (50 mL) 
and filtered through a glass fiber filter. A solution of (4S)-methyl-(1R,2R)-cyclohexane-
diaminium L-tartrate (5.566 g, 0.02 mol) in 50 mL of distilled water was added. The mixture 
was stirred for 24 h, whereby the pH of the reaction mixture was kept at 7.0 via addition of 
0.25M NaOH. After the supernatant had become almost colorless and the pH was rising 
rapidly upon further addition of the base, the yellow precipitate was filtered off via a G4 glass 
sinter filter, washed twice with 2M HCl, then three times with distilled water and dried in 
vacuum over P2O5. Yield: 7.33 g (93%), elemental analysis, found: C, 21.17; H, 3.85; N, 7,15. 
Calcd for C7H16N2PtCl2 : C, 21.33; H, 4.09; N, 7.11. 1H NMR in DMF-d7: δ = 0.96 (d, 3JH,H = 
7.5 Hz, 3H, H-7), 1.37 (m, 1H, H-5eq), 1.45 (m, 1H, H-5ax), 1.69 (m, 1H, H-3ax), 1.76 (m, 
1H, H-6ax), 1.85-1.97 (m+m+m, 3H, H-3eq, H-4eq, H-6eq), 2.48 (m, 1H, H-1ax), 2.74 (m, 
1H, H-2ax), 4.97 (m, 2H, N1-H/N2-H), 5.47 (m, 1H, N2-H), 5.60 (m, 1H, N1-H). 13C NMR in 
DMF-d7: δ =17.2 (C-7), 26.7 (C-6), 27.6 (C-4), 30.0 (C-5), 37.5 (C-3), 58.7 (C-2), 63.9 (C-1). 
15N NMR in DMF-d7: δ = –20.8 (N2), –19.9 (N1). 195Pt NMR in DMF-d7: δ = –657. 
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(1R,2R,4R)-N,N´-Bis(benzyloxycarbonyl)-4-methyl-1,2-cyclohexanedicarbamate 6 
(1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine was recovered from the respective 
diaminium tartrate 1a (0.5 g) by reaction with a NaOH solution (5 M, 25 mL) and extraction 
with dichloromethane (3 × 20 mL). Triethylamine (0.68 mL, 4.87 mmol) was added to the 
combined CH2Cl2 fractions and the reaction mixture was treated with 
benzyloxycarbonylchloride (0.57 mL, 4.05 mmol) under vigorous stirring at 0–5 °C. Then it 
was allowed to warm up to room temperature and stirred for another 3 h (TLC control, 
hexane : ethyl acetate = 3 : 1). The reaction mixture was diluted with CH2Cl2 (10 mL), 
washed with brine (2 × 15 mL), and dried over Na2SO4. The solvent was removed to give a 
slightly yellow crude product which was purified by recrystallization from MeOH. Yield: 
0.2 g (30%), m.p. 178–179 °C, [ ]D 
 20 α = -24 (c = 0.5, acetone). Elemental analysis, found: C, 
69.45; H, 7.18; N, 7.36. Calcd for C23H28N2O4: C, 69.66; H, 7.12; N, 7.07. MS (ESI+) m/z 419 
[M+Na]+. 1H NMR in CDCl3: δ = 0.94 (d, 3JH,H = 6.5 Hz, 3H, H-7), 1.08–0.93 (m, 2H, H-3, 
H-5), 1.32 (m, 1H, H-6), 1.54 (m, 1H, H-4), 1.72 (m, 1H, H-5´), 2.09–2.05 (m, 2H, H-3´, H-
6`), 3.46-3.36 (m, 2H, H-2, H-1), 5.12–5.04 (m, 6H, OCH2, NH), 7.34 (s, 10H, H-ar). 13C 
NMR in CDCl3: δ = 22.0 (C-7), 31.9 (C-4), 32.6 (C-5), 33.7 (C-6), 41.6 (C-3), 55.5 (C-2), 
55.7 (C-1), 67.0 (OCH2), 128.3 (C-ar), 128.4 (C-ar), 128.9 (C-ar), 137.0 (Cq-ar), 157.2 
(C=O). 
 
(1S,2S,4S)-N,N´-Bis(benzyloxycarbonyl)-4-methyl-1,2-cyclohexanedicarbamate 7 
Following the same procedure as described for 6, compound 7 was obtained from 1b 
(0.1 g,). Yield: 0.76 mg (53%), m.p. 179–180 °C, [ ]D 
 20 α = +24 (c 0.5, acetone). Elemental 
analysis, found: C, 69.46; H, 7.26; N, 7.08. Calcd for C23H28N2O4: C, 69.66; H, 7.12; N, 7.07. 
MS (ESI+) m/z 419 [M+Na]+. 1H NMR in CDCl3: δ = 0.94 (d, 3JH,H = 6.5 Hz, 3H, H-7), 1.08–
0.93 (m, 2H, H-3, H-5), 1.32 (m, 1H, H-6), 1.54 (m, 1H, H-4), 1.72 (m, 1H, H-5´), 2.09–2.05 
(m, 2H, H-3´, H-6`), 3.46-3.36 (m, 2H, H-2, H-1), 5.12–5.04 (m, 6H, OCH2, NH), 7.34 (s, 
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10H, H-ar). 13C NMR in CDCl3: δ = 22.1 (C-7), 31.9 (C-4), 32.6 (C-5), 33.6 (C-6), 41.5 (C-
3), 55.5 (C-2), 55.7 (C-1), 67.0 (OCH2), 128.3 (C-ar), 128.4 (C-ar), 128.9 (C-ar), 137.0 (Cq-
ar), 157.2 (C=O).  
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Solid-phase synthesis of oxaliplatin–TAT peptide bioconjugates
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Platinum-based drugs play a crucial role in the ﬁght against cancer. Oxaliplatin, which is used in the
treatment of colorectal carcinoma, was the last platinum-based agent to be approved worldwide. However,
the efﬁciency of the therapy is limited for example by a low accumulation of the drug in cancer cells.
Cell-penetrating peptides (CPPs) are known to ease the cellular membrane transport and are used as
vectors for low-molecular-weight drugs and drug carriers; of them, TAT peptides are the best-studied
group. In this work, a TAT-peptide fragment (YGRKKRRQRRR) was for the ﬁrst time conjugated to a
platinum(IV) analog of oxaliplatin as a vehicle for membrane penetration. Solid-phase peptide synthesis
and subsequent coupling with the platinum complex afforded mono- and difunctionalized conjugates,
which were separated by preparative HPLC and characterized by analytical HPLC, ESI-MS, and 1H NMR
spectroscopy. Both conjugates are active in the low micromolar range in CH1 and SW480 human cancer
cells, requiring much lower concentrations than the untargeted analogs for equal effects.
Introduction
From their beginning with cisplatin, whose anticancer properties
were discovered in the 1960s,1,2 the structures of platinum
agents underwent considerable changes in a long history of drug
development, resulting in 2nd (carboplatin) and 3rd (oxaliplatin,
Fig. 1) generations of platinum-based drugs.3–6 But the core, a
platinum atom with two coordinated N-donor functions,
remained the same together with the major shortcomings of par-
ental cisplatin—adverse side effects and limited efﬁciency of
platinum-based therapy.
Nuclear DNA is believed to be the ultimate target for cisplatin
and analogs. Reacting with N-7 of guanine and forming intra-
strand cross-links, cisplatin causes DNA bending and unwind-
ing,7 followed eventually by apoptosis.
The latest successfully approved platinum complex, oxalipla-
tin, has a slightly different mode of action and is used in meta-
static colorectal cancer, which is inherently resistant to cis- and
carboplatin. The chelating oxalate ligand is more inert as leaving
group compared to chlorides, lowering the aquation rate and thus
the risk of undesired side reactions. Additionally, oxaliplatin-
derived DNA adducts are processed differently by the cellular
machinery in comparison to those of cis- and carboplatin. Pt(IV)
complexes have signiﬁcantly lower ligand exchange rates,
compared to their Pt(II) counterparts, which might be of interest
in order to ameliorate systemic toxicity.
It is widely accepted that platinum(IV) complexes act as pro-
drugs which have to be reduced to the corresponding platinum(II)
analogs before displaying their anticancer potential (activation
by reduction). With the octahedral geometry of platinum(IV)
complexes, two extra ligand sites are introduced, which may be
used for drug targeting strategies. In this context it is worthwhile
mentioning that upon reduction of Pt(IV) to Pt(II) these extra
ligands (e.g. targeting groups) are lost, producing the original
cytotoxic platinum(II) complex.
Short amino acid sequences have already been used as target-
ing moieties for Pt(II)8 and Pt(IV)9 cisplatin analogs. However,
Fig. 1 Chemical structures of oxaliplatin, tetraplatin, satraplatin, and
complexes 1 and 4.
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coupling of different peptides to other clinically approved anti-
cancer agents such as oxaliplatin is still of high interest. Depend-
ing on the amino acid sequence, not only basic parameters such
as lipophilicity or water solubility can be changed, but more
complex interactions of the drug with the microenvironment may
be inﬂuenced. One of the authors has reported the synthesis of
peptide conjugates with organometallic complexes,10–14 for
example for intracellular delivery15–17 and targeting peptide
receptors.18–21 In one case, enhanced permeation through the
blood–brain barrier was observed for an enkephalin conjugate
with the iron-containing ferrocene moiety.22 Low cellular
accumulation is one of the main reasons for drugs to be ineffec-
tive,23 and the uptake itself depends on the ability of molecules
to penetrate the cell membrane. In this respect cell-penetrating
peptides may be very useful. These are a group of peptides
capable of translocating across the cellular membrane through
diverse pathways.24 Among these are several lysine and arginine
rich sequences. The TAT-peptide especially is well-known and
has been studied in detail.
The TAT protein (Trans-Acting Activator of Transcription) of
HIV-1 was discovered in 1987. The minimal region required for
membrane translocation was determined, namely residues 47–57
(YGRKKRRQRRR). This peptide facilitates intracellular deliv-
ery of various cargos like drug agents with limited cell per-
meability, larger biomolecules and even carriers such as
liposomes and nanoparticles.25 Later on, another important
advantage was found, namely that TAT-coupled proteins may
overcome the main obstacle in brain cancer treatment, the blood–
brain barrier.26,22 Consequently, the focus of the present work
was to combine the properties of the TAT peptide with the cyto-
toxicity of an established anticancer drug, oxaliplatin. As syn-
thetic platform, the corresponding platinum(IV) complex should
be used.
Results and discussion
Synthesis and characterization
The platinum precursor 1 was chosen because of several reasons.
Recently, the cytotoxicity of non-targeted Pt(IV) complexes was
tested in our group, and the derivatives of oxaliplatin showed
moderate antiproliferative activity compared to cisplatin
analogs.27 Targeting of a less active molecule should demon-
strate a more pronounced effect than targeting of a complex that
already has inherently high cytotoxicity. Furthermore, the choice
of oxalate as leaving group seemed advantageous. The stability
of platinum(IV) complexes in the organism plays a crucial role,
especially in the case of attached targeting moieties, which must
not be released too early (before reaching the tumor).
It is known that tetraplatin (two equatorial and two axial chlor-
ido ligands) is reduced within seconds in the blood stream.
When replacing the axial chlorido ligands by carboxylates, the
reduction is slowed down as found for satraplatin (6.3 min).28
Upon replacing the equatorial chlorido ligands with carboxy-
lates, the reduction potential again decreases29 and the resulting
compound (e.g. oxaliplatin derivative) should be equipped with
a higher stability. Besides kinetics, the oxaliplatin derivative was
chosen with consideration of future RP-HPLC puriﬁcation of the
products. The lipophilic R,R-cyclohexane-1,2-diamine ligand in
oxaliplatin (in comparison to the ammonia ligands in cisplatin)
was preferred for the synthesis of TAT-conjugates in order to
facilitate the separation of multiply positively charged molecules
(TAT has six arginine and two lysine residues) on RP-HPLC.
The peptide was synthesized manually by a solid-phase method
according to Scheme 1.
In contrast to a recently published procedure,9 coupling of
activated 1 with the deprotected peptide was not performed after
Scheme 1 Preparation of conjugates 2 and 3.
3002 | Dalton Trans., 2012, 41, 3001–3005 This journal is © The Royal Society of Chemistry 2012
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cleavage of the peptide in solution due to the undesired reaction
of the free amino groups of lysine with the platinum center.
Rather, the conjugation step was also performed using the
polymer-bound peptide with protected side chains. The platinum
precursor complex was activated with CDI as described for the
synthesis of non-targeted analogs.27,30,31 The complex is readily
soluble in DMF and can therefore be used as a building-block in
solid-phase peptide synthesis without any problems. According
to the chosen strategy, two products are expected, namely the
monoconjugate 2 and the diconjugate 3. Their ratio will inter
alia depend on the distance between the peptide chains on the
resin beads. Indeed, both conjugates could be isolated after
cleavage and deprotection using reverse-phase HPLC.
The hydrophilic properties of the TAT-peptide required a pro-
longed running time for separation of mono- and diconjugates.
The chromatograms are shown in Fig. S1 in the ESI.†
The purity of the conjugates was conﬁrmed by analytical
HPLC (Figures S1 and S2, ESI†). Characterization using
ESI-MS was troublesome because multiply charged species were
formed, for example, in the case of the monoconjugate
(M+2H+)2+, (M+3H+)3+ and for the diconjugate (M+6H+)6+,
(M+7H+)7+, (M+8H+)8+, (M+9H+)9+ ions were observed.
Besides signals of the conjugates, signals of the succinate–TAT
fragment were also observed, for both conjugates 2 and 3
(Figures S3 and S4, ESI†). The latter species turned out to be
characteristic in mass-spectra of the conjugates not only when
the electro-spray ionization method was used. In MALDI-TOF
spectra the same ion (but monocharged) was found (Figure S5,
ESI†). Differentiation between mono- and diconjugate could
also be accomplished via their 1H NMR spectra; especially the
CH–N methine protons of the cyclohexanediamine unit, the
methylene protons of the succinate moiety and the Cα-protons of
the peptide were very useful in this respect. The characteristic
regions of mono- and diconjugate (2.25–5.0 ppm) are shown in
Fig. 2. The two CH–N protons of the coordinated cyclohexane-
diamine ligand resonate at 2.79 (2) and 2.77 (3) ppm, respec-
tively. Obviously, as expected, the pattern of the CH2 protons of
the succinate moieties, which can be found in the region
between 2.35 and 2.6 ppm, is markedly different. In the case of
the diconjugate 3, two multiplets were detected, since both succi-
nate units are identical. However, in the monoconjugate 2, only
one of the succinates was derivatized, resulting in three or four
partly overlapping resonances. Additionally, the amounts of
mono- and diconjugation can also be calculated from the inte-
gration ratios of the Cα-protons (3.6–4.5 ppm) relative to the
CH–N and the succinate CH2 protons. For monoconjugate 2 a
ratio of 12 : 2 : 8 was found, whereas for the diconjugate 3, it
was 24 : 2 : 8.
Cytotoxicity in cancer cell lines
The cytotoxicity of conjugates 2 and 3 in comparison to precur-
sor 1 and non-targeted amide derivative 4 (Fig. 1) was examined
in four human cancer cell lines derived from ovarian carcinoma
(CH1, SK-OV-3), colon carcinoma (SW480) and lung adenocar-
cinoma (A549) by using the MTT assay. The results are pre-
sented in Table 1, concentration-effect curves are shown in
Figure S6 in the ESI.†
Both novel conjugates, 2 and 3, showed promising antiproli-
ferative activity with IC50 values in the low micromolar range
(1.4–31 μM). Notably, they were signiﬁcantly more active than
the non-targeted analogs 1 and 4. The carboxylic acid derivative
1 showed the lowest cytotoxicity. This is readily explained by its
low lipophilicity due to two carboxylic acid groups, resulting in
a low cellular accumulation. In contrast, the cytotoxic potency of
the non-targeted amide derivative 4 is three to ﬁve times higher
than that of 1. This ﬁnding is in accord with previous investi-
gations of analogous platinum(IV) complexes.32,33 The highest
cytotoxicity was observed for targeted conjugates 2 and 3 in
CH1 cells; with the monoconjugate 2 being up to 39 and 8 times
more cytotoxic than the non-targeted carboxylate 1 or amide 4,
respectively. In general, all IC50 values of the monoconjugate
were slightly lower in all cell lines compared to those of the
diconjugate. In that context it is worthwhile mentioning that the
TAT peptide alone features a rather low cytotoxic potency in
A549, HeLa, or CHO cancer cells.34
Experimental section
Materials and instrumentation
All chemicals and solvents were used as received from commer-
cial suppliers. (OC-6-33)-Bis(3-carboxypropanoato)(trans-
(1R,2R)-diaminocyclohexane)oxalatoplatinum(IV), complex 1,
Fig. 2 1H NMR spectra of 2 (left) and 3 (right) in D2O, showing the region between 2.25 and 5.0 ppm.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 3001–3005 | 3003
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was synthesized according to a literature procedure.27 The Fmoc-
Rink-Amide AM resin (0.59 mmol g−1), 1-hydroxybenzotriazole
monohydrate (HOBT monohydrate), 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium tetraﬂuoroborate (TBTU), N,N,N-di-
isopropylethylamine (DIPEA), triﬂuoroacetic acid (TFA) and pro-
tected acids (Fmoc-Arg(Pbf )-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-L-Tyr(tBu)-OH) were pur-
chased from Iris Biotech (Germany). N,N′-Carbonyldiimidazole
(CDI), piperidine and phenol were purchased from Sigma–
Aldrich Handels GmbH, extra dry DMF was purchased from
Acros Organics. Syringe reactors for the peptide synthesis were
purchased from MultiSynTech GmbH. Conjugates were puriﬁed
using a preparative GROM Saphir C18 column (25 mm ×
250 mm) on an Agilent 1200 series HPLC instrument. HPLC
analysis was performed on a Dionex Summit system controlled
by the Dionex Chromeleon 6.60 software using Agilent
ZORBAX Bonus-RP column (4.6 mm × 250 mm).
1H NMR spectra were recorded with a Bruker Avance III
500 MHz NMR spectrometer at 500.32 MHz in D2O at room
temperature, using the solvent residual peak for 1H as internal
reference. Electrospray ionization mass spectrometry was per-
formed on a Bruker Esquire 3000 instrument. Matrix-assisted
laser desorption/ionization time of ﬂight (MALDI-TOF) mass
spectra were measured on a Bruker Daltonics Autoﬂex with sina-
pinic acid as matrix.
Synthesis of conjugates
The Fmoc-protected TAT-peptide was manually synthesized on a
Rink amide resin (0.2 mmol, 339 mg) according to the standard
Fmoc procedure with a 4-fold excess of amino acids
(0.8 mmol).35 TBTU (257 mg, 0.8 mmol) with addition of
HOBT (123 mg, 0.8 mmol) and DIPEA (340 μL, 3.46 mmol) in
2–2.5 mL DMF were used to activate the protected amino acids.
Deprotection of the coupled amino acids was performed using
20% piperidine in DMF. After completion of the sequence, the
resin was deprotected, washed with DMF and coupled with 1.
CDI was used to activate the carboxylic groups. Complex 1
(0.4 mmol, 253 mg) was dissolved in 1.5 ml of dry DMF and
heated to 60 °C. A solution of CDI (136 mg, 0.84 mmol) in
2 mL of dry DMF was added and the mixture was stirred at
60 °C for 10 min. The mixture was cooled to room temperature
under slow argon ﬂushing; it was transferred into a reactor
containing the protected polymer-bound peptide and stirred for
24 h. After the conjugation, the excess of activated precursor
was removed, the resin was washed with DMF and dichloro-
methane and dried in vacuo. The conjugates were cleaved from
the resin using a TFA–water–phenol (95 : 2.5 : 2.5) mixture (2 h)
and precipitated with cold ether.
Crude products were dissolved in a mixture of 0.1% TFA in
water and 0.1% TFA in methanol (80 : 20) and puriﬁed using a
HPLC (trace and gradient conditions are shown in Figure S1 in
the ESI†). The monoconjugate was eluted at 32 min, followed
by the diconjugate at 35 min. The fractions, containing the pro-
ducts, were collected and lyophilized, yielding 7.3 mg of the
monoconjugate 2 and 34 mg of the diconjugate 3 (1.7% and
4.6% with respected to the resin loading). Purity was conﬁrmed
by analytical HPLC (Figures S2 and S3 in the ESI†).
ESI-MS spectra of 2 and 3 are shown in Figures S3 and S4 in
the ESI,† and the following characteristic m/z values were found:
monoconjugate 2: 1086.5 (M+2H+)2+, 724.7 (M+3H+)3+; dicon-
jugate 3: 619.5 (M+6H+)6+, 531.1 (M+7H+)7+, 464.9
(M+8H+)8+. In MALDI-TOF MS measurements, only the TAT-
succinate moieties were found: monoconjugate 2 1659.9; dicon-
jugate 3 1660.0. calculated: (+H)+ 1658.9 (Figure S5 in the
ESI†).
Cell lines and culture conditions
CH1 (ovarian carcinoma, human) cells were donated by Lloyd
R. Kelland (CRC Centre for Cancer Therapeutics, Institute of
Cancer Research, Sutton, U.K.). A549 (non-small cell lung
cancer, human) and SW480 (colon carcinoma, human) cells
were kindly provided by Brigitte Marian (Institute of Cancer
Research, Department of Medicine I, Medical University of
Vienna, Austria), and SK-OV-3 (ovarian carcinoma, human)
cells by Evelyn Dittrich (General Hospital, Medical University
of Vienna, Austria). Cells were grown in 75 cm2 culture ﬂasks
(Iwaki/Asahi Technoglass) as adherent monolayer cultures in
Minimal Essential Medium (MEM) supplemented with 10%
heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, and
4 mM L-glutamine and 1% v/v non-essential amino acids (from
100x stock solution) (all purchased from Sigma–Aldrich)
without antibiotics. Cultures were maintained at 37 °C in a
humidiﬁed atmosphere containing 5% CO2 and 95% air.
Cytotoxicity tests in cancer cell lines
Cytotoxicity in the cell lines mentioned above was determined
by the colorimetric MTT assay (MTT = 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazolium bromide, purchased from
Fluka). Cells were harvested from culture ﬂasks by trypsinization
and seeded in 100 μL aliquots in complete culture medium into
96-well microculture plates (Iwaki/Asahi Technoglass) in the fol-
lowing densities, to ensure exponential growth of untreated con-
trols throughout the experiment: 1.5 × 103 (CH1), 3.5 × 103
(SK-OV-3), 4.0 × 103 (A549), and 2.5 × 103 (SW480) viable
cells per well. Cells were allowed to settle and resume exponen-
tial growth in drug-free medium for 24 h, followed by the
addition of dilutions of the test compounds in 100 μL/well of the
same medium. After continuous exposure for 96 h, the medium
Table 1 Cytotoxicity of conjugates 2 and 3, precursor complex 1, and
its amide derivative 4 in four human cancer cell lines
Compound
IC50 [μM]
a
CH1 A549 SW480 SK-OV-3
1b 55 ± 28 n.d. 44 ± 9 142 ± 26
2 1.4 ± 0.3 11 ± 2 3.2 ± 0.4 22 ± 3
3 2.5 ± 0.6 23 ± 4 4.8 ± 1.6 31 ± 4
4b 11 ± 2 n.d. 12 ± 5 44 ± 10
a 50% inhibitory concentrations in CH1, A549, SW480 and SK-OV-3
cells in the MTT assay, 96 h exposure. Values are the means ± standard
deviations obtained from three independent experiments. b data taken
from ref. 27.
3004 | Dalton Trans., 2012, 41, 3001–3005 This journal is © The Royal Society of Chemistry 2012
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was replaced by 100 μL/well RPMI 1640 medium (sup-
plemented with 10% heat-inactivated fetal bovine serum and
4mM L-glutamine) plus 20 μL/well solution of MTT in phos-
phate-buffered saline (5 mg mL−1) (all purchased from Sigma-
Aldrich). After incubation for 4 h, medium–MTT mixtures were
removed, and the formazan product formed by viable cells was
dissolved in DMSO (150 μL/well). Optical densities at 550 nm
were measured with a microplate reader (Tecan Spectra Classic),
using a reference wavelength of 690 nm to correct for unspeciﬁc
absorption. The quantity of viable cells was expressed as a per-
centage of untreated controls, and 50% inhibitory concentrations
(IC50) were calculated from concentration-effect curves by
interpolation. Evaluation is based on means from three indepen-
dent experiments, each comprising six replicates per concen-
tration level.
Conclusions
Mono- and difunctionalized conjugates of an oxaliplatin prodrug
were prepared for the ﬁrst time by solid-phase peptide synthesis
and characterized by 1H NMR spectroscopy, ESI-MS and
analytical HPLC. Remarkably, inhibition of cancer cell prolifer-
ation requires only low micromolar concentrations of the conju-
gates. Compared to its non-targeted platinum(IV) analogs, the
monoconjugate was up to a factor of 39 more cytotoxic. These
results are very promising and warrant further studies in vitro
and especially in vivo.
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 S2
Figure S1. HPLC purification of of conjugates 2 and 3. Column: GROM Saphir C18 
column (25 mm × 250 mm), eluents: 0.1% TFA in water and 0.1% TFA in methanol. 
Monoconjugate 2 was eluted at 32 min, diconjugate 3 at 35 min. 
 
 
 
 
 
 
 
Gradient conditions:  
 
time, min % MeOH Rate, ml/min 
0 20 20 
25 20 20 
35 40 20 
45 20 20 
 
 
 
 
 
min5 10 15 20 25 30 35 40
Norm.
-10
0
10
20
30
40
50
60
 MWD1 A, Sig=254,4 Ref=550,100 (DACHPT_TAT_EDA\RUN000001.D)
 5
.1
62
 3
1.
20
9
 3
2.
22
0
 3
4.
12
0
 3
4.
84
4
 3
6.
15
2
 3
6.
52
3
 3
7.
25
5
 3
7.
78
1
 3
7.
94
5
 3
8.
20
9
 3
8.
38
4
 3
8.
45
8
 3
8.
51
5
 3
8.
61
0
 3
8.
68
0
 3
8.
77
5
 3
8.
82
1
 3
8.
90
7
Electronic Supplementary Material (ESI) for Dalton Transactions
This journal is © The Royal Society of Chemistry 2012
63
 S3
Figure S2. Analytical HPLC traces of purified conjugates 2 (A, 9.28 min) and 3 (B, 
9.74 min). Column : Agilent ZORBAX Bonus-RP (4.6 mm × 250 mm ), eluents: 0.1% 
TFA in water and 0.1% TFA in methanol. 
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Figure S3. ESI-MS characterization of conjugate 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
     (M+3H+)3+=724.7 
 
 
     (TAT-Succinate+2H+)2+=830.0 
 
 
 
 
 
 
     (M+2H+)2+=1086.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monoconjugate 2: Exact Mass:  2171.05 
TAT-Succinate: Exact Mass: 1657.98 
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Figure S4. ESI-MS characterization of conjugate 3.  
 
 
 
 
 
 
 
 
 
  (TAT-Succinate+4H+)4+=415.24 
 
 
 
 
 
 
 
 
  (TAT-Succinate+5H+)5+=332.39 
 
 
 
 
 
 (M+9H+)9+=413.3 
 (M+8H+)8+=464.9 
 (M+7H+)7+=531.1 
 (M+6H+)6+=619.5 
 
 
 
Diconjugate 3: Exact Mass: 3711.01 
TAT-Succinate: Exact Mass: 1657.98 
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Figure S5. MALDI-TOF characterization of conjugates 2 and 3.  
 
Found for monoconjugate: 1659.9 
 
 
 
       Calculated: 
       C68H123N33O16 
Exact Mass: 1657.98 
Mol. Wt.: 1658.92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Found for diconjugate: 1660.0 
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 S7
Figure S6. Concentration-effect curves of conjugates 2 and 3 and the precursor 
complex 1 and its amide derivative 4 in CH1 (A), SK-OV-3 (B), SW480 (C) and 
A549 (D) cell lines obtained by the MTT assay (96 h exposure) 
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Optimization of the Coupling Strategy of Pt(IV) Complexes to Peptides 
 
The ability of appended peptides to modify cytotoxic properties of platinum compounds 
was demonstrated with Pt(II) and Pt(IV) complexes. Both mono- and bisconjugates with the 
TAT peptide were more active, compared to the starting compound and an analog without a 
targeting group. The vectors increased the cytotoxicity of the complexes, other peptides, 
containing the RGD motif (a sequence, able to bind to receptors on the cell surface, integrins) 
increased their selectivity towards some cell lines. 
The comparable activity of both conjugates suggests, that the synthetic strategy can be 
aimed at obtaining a single product. A platinum complex with one peptide moiety is 
preferred, the other route wastes one peptide chain. This goal can be achieved by using 
monofunctionalyzed Pt building blocks. One of the axial positions of Pt(IV) complexes can be 
blocked on the stage of oxidizing Pt(II) complexes. When the reaction is performed in non-
aqueous medium, the unsymmetrical monohydroxido monosolvato complexes are formed, 
according to the following equation: 
 
N
H2
Pt
H2
N
O
O O
O NH2
Pt
H2
N
O
O O
O
OH
O
O
CH3
N
H2
Pt
H2
N
O
O O
O
O
O
O
CH3
O
O
OH
O OO
H2O2
CH3COOH
 
Initially synthesis of Pt(IV) conjugates with shorter sequences was performed in solution, 
but it would be troublesome for longer sequences containing numerous basic amino acids. 
Besides reaction with side-chain amino groups, there was another disadvantage of the method. 
Both activated carboxylic groups of starting platinum compounds could react. Later, the 
solution-state derivatization of the cisplatin analogs with a longer, 36 amino acid peptide 
chlorotoxin was developed, based on different basic properties of terminal amino groups of 
the peptide and ε-aminogroup of lysines.1 The platinum complexes were taken in excess (5:1 
or 10:1) to find better conditions for the synthesis. 
It’s obvious that a straightforward solution-state strategy for selective conjugation is 
necessary for the development of more complex conjugates. This will allow avoiding 
cleavage under aggressive conditions and application of scavengers like triisopropylsilane 
(TIS) and ethanedithiol. Reaction of thiols with maleimide is a widely used methodology for 
effective crosslinking under milder conditions. Equipment of platinum precursors with a 
69
maleimide functionality opens up a way to append different peptides via an additional 
cysteine. The only prerequisite of this strategy is the absence of cysteine in the peptide chain. 
The reaction is normally performed in a slightly basic environment in phosphate buffer, but 
other bases can be used instead.2  
Bombesin was chosen as a delivery vector for the cytotoxic complex. It is a neuropeptide 
with many biological functions, its receptors are overexpressed in many tumors including 
breast, prostate, intestine, pancreas and brain tumors. Previously, it was used for diagnostic 
purposes, but its potential could be helpful in therapy as well.3 
Oxaliplatin was synthesized as described in the literature.4 
Oxidation of oxaliplatin with hydrogen peroxide in acetic acid afforded the corresponding 
Pt(IV) complex with the oxaliplatin core and the axial acetato and hydroxido ligands. The 
symmetrical dihydroxido byproduct could be separated because of the lower solubility in a 
methanol/ethyl acetate mixture; traces of the diacetato complex were inert in the next step and 
were removed after the acylation step. 
Two carboxylic acid anhydrides were used to prepare the platinum precursors for the 
conjugate synthesis. The complex with free carboxylic acid group was obtained via reaction 
with succinic anhydride as described for the symmetrical dihydroxido complexes. The 
symmetric anhydride for the synthesis of the maleimido-derived complex was prepared from 
the corresponding carboxylic acid and triphosgene. 
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(OC-6-44)-Acetato(R,R-1,2-diaminocyclohexane)hydroxido(oxalato)platinum(IV) 
 
N
H2
Pt
H2
N
O
O O
O NH2
Pt
H2
N
O
O O
O
OH
O CH3
O
H2O2
CH3COOH
 
 
1.19g (3 mmol) of oxaliplatin were suspended in 20 mL of acetic acid, and 0.25 mL of 
30% H2O2 were added. The mixture was stirred for 30 min, then the next 0.25 mL portion of 
hydrogen peroxide was added. After 30 minutes a third portion was added (0.75 mL). In 1.5 
hours the solution turned yellowish and almost clear. The mixture was stirred overnight.  
Acetic acid was removed on a rotary evaporator and the oily residue was suspended in water 
(40 mL), forming a turbid solution. Addition of water, suspending and removal of water on a 
rotary evaporator was performed 2 times more till the product became solid. The product was 
suspended in ethyl acetate, methanol was added stepwise till the solution turned almost clear 
and the addition of a next portion of methanol did not change the appearance. The mixture 
was filtered through a glass sinter filter, the solvent was removed on a rotary evaporator, and 
the white, slightly yellowish product was dried in vacuum 
Yield: 0.975g (69%) 
 
1H NMR (DMSO): δ = 8.70 – 8.48 (bs, 1H, NH2), 8.26 – 8.06 (bs, 1H, NH2), 7.89 – 7.68 
(bs, 1H, NH2), 7.19 – 7.00 (bs, 1H, NH2), 2 protons superimposed by DMSO signal, 2.13 – 
2.01 (m, 2H, chxn), 1.92 (s, 3H, CH3), 1.54 – 1.41 (3H, chxn), 1.39 – 1.30 (1H, chxn), 1.24 (s, 
1H, OH), 1.15 – 1.09 (m, 2H, chxn) ppm 
 
13C NMR (DMSO): δ = 180.3 (C(O)CH3), 164.3 (2C, C(O), oxalate), 61.9, 60.5 (2C, CH, 
(chxn)), 31.4, 31.2 (2 C, CH2, (chxn)), 24.4 (CH3, acetato), 24.1, 24.1 (2C, CH2, (chxn)) ppm 
 
195Pt NMR (DMSO): δ = 3033 ppm 
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(OC-6-44)-Acetato (3-carboxypropanoato) (R,R-1,2-diaminocyclohexane) 
oxalatoplatinum(IV) 
N
H2
Pt
H2
N
O
O O
O
OH
O CH3
O
O OO
N
H2
Pt
H2
N
O
O O
O
O
O CH3
O
O
O
OH
 
 
0.770 g (1.65 mmol) of the hydroxido complex was mixed with 0.400 g (4 mmol) of 
succinic anhydride and suspended in 15 mL of DMF. The mixture was stirred overnight at 
50°. DMF was removed under high vacuum, the oil was suspended in 200 mL of acetone, and 
methanol was added stepwise till the amount of insoluble solid did not change upon addition 
of the next portion of methanol. The solution was filtered, the solvents were removed on a 
rotary evaporator and the residue was dissolved in acetone. Then, diethyl ether was added 
under vigorous stirring till the addition did not cause further precipitation (about 500 mL). 
The product was filtered, washed with ether and dried in vacuum. 
Yield: 0.805 g (90%) of unpurified product 
 
1H NMR (DMSO): δ = 12.1 (bs, 1 H, COOH), 8.52 – 8.07 (br, 4 H, NH2), 2.63 – 2.57 (m, 
2H, chxn), 2.44 – 2.34 (4H, succinato), 2.17 – 2.06 (4H, chxn), 1.96 (s, 3H, CH3), 1.54 – 1,47 
(m, 2H, chxn), 1.46 – 1.33 (m, 2H, chxn), 1.19 – 1.12 (m, 2H, chxn) ppm 
 
 
13C NMR (DMSO): δ = 180.1, 179.1 (2C, C(O)CH3, COO), 174.2 (COOH), 163.9, 163.8 
(2C, C(O), oxalate), 61.4 (2C, CH, (chxn)), 31.4, 31.3(2C, (chxn)), 31.0, 30.0 (2C, 
(succinato)), 24.0, 23.90 (2C, (chxn)), 23.4 (CH3, acetato) ppm; 
 
195Pt NMR (DMSO): δ = 3239 ppm 
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(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid 
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A suspension of maleic anhydride (10 g, 0.102 mol) and glycine (7.732 g, 0.103 mol) in 
acetic acid (100 mL) was heated at reflux for 1.5 hours, till the white solid was completely 
dissolved. Acetic acid was removed on a rotary evaporator, the residue was dissolved in 100 
mL of water and extracted with ethyl acetate (3 ×  100 mL). The extracts were dried over 
magnesium sulfate, the solvent was removed on a rotary evaporator, the product was 
recrystallized in ethyl acetate. 
Yield: 6.3 g, 40% 
 
1H NMR (DMSO): δ = 13.15 (br, 1H, COOH), 7.13 (s, 2H, C=C–H), 4.15 (s, 2H, CH2). 
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(OC-6-44)-Acetato(R,R-1,2-diaminocyclohexane)[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) 
acetato]oxalatoplatinum (IV) 
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A solution of maleimidoacetic acid (155 mg, 1 mmol) and 200 µL of triethylamine in 15 
mL of absolute THF was cooled in a ice/salt bath. Triphosgene (60 mg, 0.2 mmol) was added 
as solid. The mixture turned dark-brown and soon a white precipitate formed. After 3 hours 
the solid was filtered off and washed with tetrahydrofurane. The solution was concentrated on 
a rotary evaporator, dissolved in chloroform and the Pt complex (118 mg, 0.25 mmol) was 
added. The heterogeneous mixture was refluxed overnight. 
The product was filtered off, washed with chloroform and purified chromatographically 
(Ethyl acetate : Ethanol, 5:1, Rf =0.35) 
Yield: 38 mg (25%) 
ESI-MS: 633.0754 (Calculated for M+Na+: 633.0772) 
1H NMR (DMSO): δ = 8.33 (br, 2H, NH2), 8.28 (br, 1H, NH2), 7.78 (br, 1H, NH2), 7.09 
(s, 2H, =C−H), 4.24 (d, 2JH,H = 17.3 Hz, 1H, CH2,), 4.19 (d, 2JH,H = 17.3 Hz, 1H, CH2,) 2.56 
(m, 2H, CH, chxn), 2.12 (m, CH2, chxn), 2.10 (m, CH2, chxn), 1.96 (s, CH3, acetato), 1.44 (m, 
CH2, chxn), 1.16 (m, CH2, chxn),    
13C NMR (DMSO): δ = 179.1 (C(O)CH3), 173.3 (C(O)CH2 (glycine)), 171.0 
(C(O)(maleimide)), 164.1, 164.0 (C(O), oxalate), 135.3 (CH=CH (maleimide)), 61.7, 60.8 
(CH, (DACH)), 39.3 (CH2, (glycine)), 31.4, 31.2, 24.1, 24.0 (CH2, (DACH)), 23.4 (CH3, 
acetato) ppm; 
 
195Pt NMR (DMSO): δ = 3253.73ppm. 
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General procedure of the solid-phase peptide synthesis 
 
The resin was weighed in a glass vial and allowed to swell in DMF for 30 minutes under 
shaking, then it was transferred into a reactor (10 mL syringe with PET filter). The swollen 
resin was deprotected. 
Deprotection procedure: 
20% solution of piperidine in DMF was taken up into the syringe and shaken for 15 
minutes. The solution is removed and resin is washed 5 times with 4 mL DMF. 
The activated amino acid was taken up into the syringe. 
Activation procedure: 
TBTU ( (1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate) was 
mixed with HOBT (1-hydroxybenzotriazole) (4-fold excess in respect to the resin loading) 
and dissolved in DMF in a glass vial. This solution was added to a solid amino acid, followed 
by 10 equivalents DIPEA (diisopropylethylamine). After stirring, the solution turned yellow, 
clear and homogeneous (reaction time is about 2 minutes). 
The coupling time depended on the amino acid. For amino acids with side chain 
protective groups it was 30 min, for amino acids without side chain protection – 20 min. 
Arginine(Pbf) required a longer time (1 hour). After the coupling step, the resin was washed 
with DMF 5 times. After reaction, the Kaiser test was performed to estimate completeness of 
the coupling. If the test had been positive, the coupling was repeated. 
Kaiser test procedure:5 
Several resin beads were transferred into an eppendorf vial and washed two times with 
ethanol. Several drops of each solution were added: 
KCN in pyridine (2 ml 0.001 M KCN in 98 ml) 
Ninhydrin, 6% in ethanol (w/v) 
Phenol in ethanol, 80% (w/v) 
The resulting solution was carefully mixed and heated at 100-120°C for 4-6 minutes. If 
the solution or the resin beads are turning blue, free amino groups were present and the 
coupling had to be repeated. 
The sequence of deprotection/coupling steps was repeated subsequently for all amino 
acids. The last Fmoc-group was removed as usual, the resin was washed 5 times with DMF, 
transferred into a fresh syringe, washed 5 times with methylene chloride and dried in vacuum. 
The peptide was cleaved from the resin with a suitable mixture (Scheme 1). The syringe 
containing the acid was shaken for 2 hours, afterwards the solution was pushed out of the 
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syringe into a flask, the resin in reactor was washed once with TFA. The combined TFA 
solutions were concentrated under vacuum with the help of a membrane pump and with a 
liquid nitrogen trap. After concentration, diethyl ether was added to precipitate the product. 
 
 
Scheme 1,Taken from ref. 66 
 
The fraction containing the crude peptide was cooled with liquid nitrogen and centrifuged. 
Ether was decanted, the solid is suspended in ether, cooled and centrifuged again. The 
procedure was repeated 2 times. 
The solid is dissolved in a suitable solvent (water, methanol, acetonitrile), filtered through 
a 20 µm syringe filter and purified via RP-HPLC. 
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Glutaminyltryptophylalanylvalylglycylhistidylleucylmethioninamide 
octapeptide (Bombesin) 
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The peptide was synthesized according to the standard procedure in two reactors with 0.4 
mmol equivalents of resin in each of them. Cleavage was performed with a TFA/water/EDA 
(95/2.5/2.5) mixture. The raw peptide was purified on a C-18 RP HPLC Grom Saphir column 
in an isocratic mode with 50:50  ratio of 0.1% TFA in  methanol and water. 
Yield: 238 mg (32%). 
Calculated mass for C43 H65 N13 O9 S +H+=941.49 
ESI-MS: 941.7, 963.5 (M+Na+) 
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Cysteinylglutaminyltryptophylalanylvalylglycylhistidylleucylmethioninamide 
nonapeptde (Cysteinylbombesin) 
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The peptide was synthesized according to the standard procedure in two reactors with 0.3 
mmol equivalents of resin in each of them. Cleavage was performed with a TFA/water/TIS 
(triisopropylsilane) mixture (95/2.5/2.5), but surprisingly the purified product (isocratic, 
50/50, ~10 min) showed a signal in the mass spectrum M+244, indicating the incomplete 
removal of Trt group. 
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Separation conditions: 0.1% TFA in water and methanol 
Time    % Methanol   Rate,mL/min 
0.00        5.0        20 
20.00      95.0        20 
30.00       5.0        20 
The solid was dissolved in 10 mL TFA and several drops of TIS were added to the yellow 
solution. It became colorless immediately, indicating Trt cation scavenging; the precipitation 
step was repeated once more. 
Yield 26 mg, 4% 
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Coupling of (OC-6-44)-Acetato (3-carboxypropanoato) (R,R-1,2-diaminocyclohexane) 
oxalatoplatinum(IV) with bombesin 
Gln–Trp–Ala–Val–Gly–His–Leu–Met–NH2
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N O
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Bombesin (154 mg, 0,2 mmol) and 230 mg of the platinum precursor (230 mg, 0.4 mmol) 
were mixed in 5 mL of DMF, then EDC (81 mg, 0.42 mmol) and 100 µL DIPEA were added. 
The mixture was stirred for 24 hours, DMF was removed in vacuum and the mixture was 
dissolved in a water:methanol mixture. The solution was filtered with a membrane filter (20 
µm pore) and the filtrate was purified with HPLC. 0,1% TFA in water and methanol were 
used as mobile phase 
Time    % Methanol   Rate,mL/min 
0.00        5.0        20 
20.00      95.0        20 
30.00       5.0        20 
The product was eluted at 14.6 min 
Calculated mass of product (C57 H85 N15 O18 S1 Pt1) + H+ = 1495.56: 
ESI-MS: 1494.7 and 1040.6 (Peptide+succinate residue, M=1040.49)  
Yield: 13 mg (0.87%) 
 
79
Coupling of (OC-6-44)-acetato(R,R-1,2-diaminocyclohexane)[(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)acetato]oxalatoplatinum (IV) with cysteinylbombesin 
 
H
N CH C
CH2
H
N
O
CH2
C
NH2
O
CH C
CH2
H
N
O
HN
CH C
CH3
H
N
O
CH C
CH
H
N
O
CH3
CH3
CH C
H
H
N
O
CH C
CH2
H
N
O
N
NH
CH C
CH2
H
N
O
CH CH3
CH3
CH C
CH2
NH2
O
CH2
S
CH3
H2N CH C
O
Pt
N
H2
H2
N O
O
O
O
O
O
CH2
S
N
O
O
O
O
CH3
 
 
(OC-6-44)-acetato(R,R-1,2-diaminocyclohexane)[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)acetato]oxalatoplatinum (23 mg, 0.038 mmol) was dissolved in 2 mL of methanol and 
added to a solution of bombesin (26 mg, 0.025 mmol) in 1 mL of methanol. Potassium 
carbonate on tip of the spatula was dissolved in 200 µL of a 1:1 water methanol mixture and 
added. The solution was stirred 2 days at room temperature under argon. A white precipitate 
was formed. The mixture was dissolved in 0.1% TFA, the product was purified via RP-HPLC 
on a C-18 column, eluted at 16 min.  
 
Time    % Methanol   Rate,mL/min 
0.00        5.0        20 
20.00      95.0        20 
30.00       5.0        20 
 
Yield: 5.1 mg (12%) 
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ESI-MS (Low resolution):  
1654.0 (Calculated for [C62 H91 N17 O20 Pt S2 + H]+=1653.5794) 
Axial ligand: 1198.2 (Calculated for [C52 H76 N15 O14 S2 + H]+=1198.5) 
High resolution MS: 1653.5749  
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III. Conclusions 
 
Different types of novel oxaliplatin derivatives are described in the present 
dissertation.  
The first project focused on modification of the non-leaving cyclohexanediamine 
ligand. Two synthetic pathways were developed for selective synthesis of different isomers of 
the analogs. SP-4-3{(1R,2R,4R)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II), the 
isomer with equatorial orientation of the methyl substituent could be prepared from the 
corresponding dichlorido complex via activation with silver nitrate. Racemic 4-
methylcyclohexene was used as precursor for synthesis of the non-leaving 
methylcyclohexanediamine ligand. The alkene was converted into the trans-diol; on the next 
step, OH- groups were mesylated and substituted with azide. Reduction with 
hydrogen/palladium afforded the corresponding diamine, which could be separated into S,S- 
and R,R- isomers by recrystallization of the L-tartaric acid salt.  The analog featuring an axial 
methyl group, SP-4-3{(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine} oxalatoplatinum(II), 
required a more complex synthetic pathway. The enatiomerically pure starting compound (S)-
4-methylcyclohexene was obtained from natural (S)-citronellal via Wittig reaction and ring-
closure metathesis. The catalyst for metathesis was synthesized in situ from tungsten 
oxychloride and tetraethyl lead. (S)-4-Methylcyclohexene was converted into the diazide in 
one step using manganese triacetate and sodium azide, futher transformations were the same. 
The enantiomeric composition of the isomer mixtures was determined using a chiral 
HPLC with prior CBZ-derivatization of the diamines. Biological activity of both isomers was 
evaluated in vitro and in vivo. The isomer with an axial methyl group showed a better effect 
then its isomer exhibiting an equatorial methyl group and oxaliplatin itself in cytotoxicity test 
on all cell lines, but investigation of the activity in a leukemia mouse model brought opposite 
results. Application of the analog with an axial methyl group resulted in an increased 
anticancer activity and significantly lower toxicity compared to oxaliplatin. 5 out of 6 mice 
survived for a long time under application of the maximum tolerated dose (which was also 
higher then the one of oxaliplatin) what makes the compound worthy for further 
investigations. 
 
In the second part, Pt(IV) analogs of oxaliplatin were obtained and conjugated to the TAT 
peptide via amide bond formation. According to the structure of the starting platinum 
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complex, two products could be expected, 1:1 and 1:2 in ratio of platinum:peptide. The 
isolated complexes were characterized with NMR, mass spectrometry and analytical HPLC. 
Both substances were tested active in cytotoxicity experiments in human cell lines CH1, SK-
OV-3, (ovarian carcinoma), SW480 (colon carcinoma) and A549 (nonsmall-cell lung cancer). 
In all these experiments, the conjugates showed higher activity compared to the precursor acid 
and an analog without appended peptide. This proved the supposition, that peptides can work 
as delivery vectors for platinum complexes, facilitating their cellular transport. 
 
The third project focused on optimization of the conjugation strategy. Oxaliplatin was 
oxidized in acetic acid to keep only one hydroxo group for further reactions. The asymmetric 
complex was acylated with a symmetric anhydride, containing a maleimide fragment. 
Reaction of maleimide and a cysteine-derived peptide afforded the desired complexes under 
mild conditions and better yields. 
For that purpose, the octapeptide bombesin was chosen as tumor-homing vector, its 
receptors are expressed in many cancer cells. One conjugate was prepared using standard 
peptide coupling of the free amino group of peptide and carboxylate on the platinum 
precursor, another one was prepared using the maleimide-cysteine reaction. The conjugates 
were characterized with NMR, ESI-MS and analytical HPLC. 
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